Mary Eileen Dolan - Purdue University

CURRICULUM VITAE 

Mary Eileen Dolan 

Section of Hematology/Oncology 

Department of Medicine 

University of Chicago 

5841 S. Maryland Avenue - MC 2115 

Chicago, IL 60637 

773-702-4441 (off) 

773-702-0963 (fax) 

edolan@medicine.bsd.uchicago.edu 

Current Position 

Professor, Section of Hematology/Oncology, Department of Medicine, The University of 

Chicago, Chicago, IL. July, 2003 – present (with tenure) 

Chair, Committee on Clinical Pharmacology and Pharmacogenomics (Feb, 2010 – present) 

Academic Appointment 

Associate Professor, Section of Hematology/Oncology, Department of Medicine, The 

University of Chicago, Chicago, IL. July, 1999 - June, 2003. 

Assistant Professor, Section of Hematology/Oncology, Department of Medicine, The 

University of Chicago, Chicago, IL. October, 1992 – June, 1999. 

Research Associate (Assistant Professor), Section of Hematology/Oncology, Department of 

Medicine, The University of Chicago, Chicago, IL. September, 1989 - September, 1992. 

Research Assistant Professor, Department of Physiology, The Milton S. Hershey Medical 

Center, The Pennsylvania State University, Hershey, PA. February, 1986 - September, 

1989. 

Postdoctoral Fellow, Department of Physiology and Cancer Research Center, The Milton S. 

Hershey Medical Center, The Pennsylvania State University, Hershey, PA. October, 1983 to 

January, 1986. 

Education 

Ph.D., Purdue University, West Lafayette, IN, Medicinal Chemistry, December, 1983. 

B.S., University of Dayton, Dayton, OH, Chemistry (cum laude), April, 1979. 

Special Awards 

Purdue University School of Pharmacy Distinguished Alumni Award, 2010 

University of Dayton Distinguished Alumni Award, 2006 

American Cancer Society Ambassador of Hope, 2006 

ACS, IL Presidential Award for Volunteer Contributions to Research, 2005

Undergraduate Awards: Milacron Scholarship (3 years); American Chemical Society Award 

for Outstanding Senior in Chemistry; Award for Outstanding Service to the University; 

Chemical Rubber Company Freshman Award for Academics. 

Graduate Awards: Virginia Evans Award for excellence in graduate research from the 

Tissue Culture Association; Glenn L. Jenkins Award finalist for excellence in graduate 

research in the School of Pharmacy, Purdue University. 

Alumni Award: Marillac High School Award for outstanding academic achievement. 

Professional Society Membership 

American Association for Cancer Research 

Women in Cancer Research 

Committee Appointments 

Chair, Committee on Reappointments of Assistant Professors (2005-2010, appointed by 

Dean; responsible for advising Dean on 60-80 Assistant Professors/year); Vice-Chair 

(2004-2005); Member (2000-present) 

Chair, Committee on Clinical Pharmacology and Pharmacogenomics (2010-present) 

Executive Committee (1999-present) 

Fellowship Selection Committee (1999-present) 

Goldberg Memorial Lecture Selection Committee (2005-present) 

Pharmacogenetics of Anticancer Agents Research Group 

Executive Committee (2000-present) 

University of Chicago Cancer Research Center 

Co-Program Leader, Clinical and Experimental Therapeutics Program (2000-present) 

Director, Pharmacology Core Facility (2000-2009) 

ACS-Institutional Research Grant Review Committee (1999-present) 

UCCRC Grant Reviewer (2007-present) 

Member of the University Council of the Senate (2004-2007) 

Committee on Cancer Biology 

Curriculum Committee (2001-2006) 

Steering Committee (2006-present) 

University Benefits Committee (2009-present) 

Department of Medicine Space Allocation Committee (2010-present) 

Fellowship Selection Committee for Hematology-Oncology (1997-2000) 

Animal Protocol Review Committee for Dept. Medicine (1998-2005) 

Dean‘s Special Committee on the Integration of Core Facilities (1998-1999) 

KCBD Move Leader 

Overall responsibility for move of 23 faculty and their respective laboratories from various 

locations on campus and the medical center to Knapp Center for Biological Discovery (2008-2009) 

Programs Initiated 

Chicago Experimental Therapeutics Group, 1998-2003 

Scientific meetings dedicated to presenting both preclinical and clinical research relating 

to investigational anti-cancer therapies or novel approaches to cancer treatment. This 

group meets four times a year and is attended by investigators from all major medical 

schools in Chicago. The format includes dinner at each session followed by two 20 

minute presentations and discussion. Locations rotate between University of Chicago, 

Northwestern University and University of Illinois at Chicago. 

2

Teaching Responsibilities 

Pharmacogenetics: Creator and Director of Course (Spring quarter, 2010) 

Cancer Biology IV: Frontiers in Cancer Research, Director of Course (2002, 2004, 2006): 

―Exploiting Molecular Targets in Cancer Therapy.‖ Responsible for all lectures, problem 

sets, overall course design, arranging outside speakers, grading students. 

Institutional Training Program in Psychiatric Genetics – ―Multidisciplinary Approaches in 

Psychiatric and Behavioral Genetics‖, lecture entitled, ―Pharmacogenetics‖ (5/2005) 

University of Chicago Cancer Research Center – CCTO, lecture entitled, ―Drug Discovery‖ 

(5/2005) 

Cancer Biology/Pathology Course – ―Molecular Mechanisms in Cancer Biology‖ lecture 

entitled ―DNA Repair‖ (2004) 

Department of Neurobiology, Pharmacology and Physiology (2003-2007), ―Principles of 

Pharmacology.‖ Responsible for 1-2 lectures per year. 

Grantsmanship Lecture Series, 1 lecture/year (2006-2007) 

Cancer Genetics Seminar Series, 2 lectures (2/2007, 10/2007) 

Cancer Biology IV: Frontiers in Cancer Research, Co-Director of course (2000 and 2001): 

―Molecular approaches to treat metastatic disease,‖ responsible for 8 lectures, problem sets, 

course design, arranging outside speakers, grading students. 

Cancer Biology IV: Frontiers in Cancer Research, Lecturer (1996-1999) 5-7 lectures/year. 

Introduction to Hem/Onc Fellowship Program, Lecturer (1994-2007) 1 Drug Development 

lecture/year. 

Hematology/Oncology Summer Seminar Series Lecturer (2004-2005) 1 lecture/year 

Hematology/Oncology and Cancer Center Research Seminar Series, Director (1991-2005) 

Responsible for arranging 15-18 seminar speakers/year. 

Graduate Committees 

Upendra Marathi, Loyola University, PhD Committee 

(Graduated 4/94) 

Susan Morgan, Loyola University, PhD Committee 


Sonal Patel, Loyola University, PhD Committee 


Thelma Tennant, Cancer Biology, University of Chicago, PhD Committee 


Emma Thompson, Dept. of Genetics, University of Chicago, PhD Committee 


Leslie Woo, Biochemistry and Molecular Biology, University of Chicago, PhD 

Committee 

3

Christy Hagan, Cancer Biology, University of Chicago, PhD Committee 


Yanwen Jiang, Cancer Biology, University of Chicago, PhD Committee 


Colleen Jones, PhD Student, University of Chicago, Rotating Student 

-recipient of NSF Fellowship 

Paul LaPorte, Cancer Biology, University of Chicago, PhD Committee 

Timothy Lewis, Cancer Biology, University of Chicago, Rotating Student 

Nora Wasserman, Committee of GeneticS, University of Chicago, Rotating Student 

Sapana Vora, Cancer Biology, University of Chicago, Rotating Student 

Laboratory Trainees 

Clinical Pharmacology and Pharmacogenomics Fellows 

Reginald Ewesuedo, MD 

-recipient of ASCO Young Investigator Award for work in my laboratory, (1998 – 

2000) 

-Current position: AstraZeneca, Director of Clinical Research 

Rod Humerickhouse MD, PhD 

-recipient of ASCO Young Investigator Award for work in my laboratory, (1998 – 

2000) 

-Current position: Abbott Labs, North Chicago, IL 

R. Nagasubramanian, MD 

-recipient of CALGB Grant (2000-2004) 

-Current position: Pediatric Hematology-Oncology, Nemours Children‘s Clinic, 

Orlando, FL 

Rong (Stephanie) Huang (2005-2009) 

-chosen for oral presentation at Pharmacogenomics Meeting CSHL, 2006 

-chosen for Scholar in Training Award for AACR Molecular Diagnostics in Cancer 

Therapeutic Development meeting, Chicago, IL, 2006 

-Selected for oral presentation at 2006 AACR International Conference on Molecular 

Diagnostics in Cancer Therapeutic Development, Chicago, IL 

-Charles Huggins Lectureship Awardee, 2007 

- selected for American Society of Clinical Pharmacology and Therapeutics (ASCPT) 

Presidential Trainee award, 2007 meeting 

-chosen for oral presentation at ASCPT, 2007 

-chosen for 2007 AACR-Merck Scholar in Training Award 

-recipient of Best Poster for Midwest Bioinformatics meeting, 2007 

-chosen to present at CSHL Pharmacogenetics Meeting, November 2008 

-Current Position: Assistant Professor of Medicine, University of Chicago 

Christine Hartford, MD (2006 – 2008) 

-selected for platform presentation at American Society of Pediatric Oncologists 

meeting, 2007 

-selected for ASCPT Presidential Trainee Award, 2008 

-recipient of AYA-Aflac Young Investigator Award, 2008 

- Current position: Assistant Professor, Section of Pediatric, Hematology- 

Oncology, University of Chicago 

Peter O‘Donnell, MD, (2007-2010) 

-chosen for oral presentation at 2008 AACR meeting, San Diego, CA 

- Aflac-AACR Scholar-in-Training Award, American Association of Cancer 

Researchers (AACR) Annual Meeting (April 2008) 

4

- chosen for oral presentation at ASCPT Annual Meeting, National Harbor, MD, March 

2009 

- chosen for oral presentation at Translational Breast Cancer Research Consortium 

Meeting, Dallas, TX, March 2009. 

-John Quale Travel Fellowship Award for Young Investigators, Bladder Cancer 

Advocacy Network 4 th Annual Bladder Cancer Think Tank Meeting (2009) 

- American Society of Clinical Pharmacology and Therapeutics (ASCPT) Presidential 

Training Award, ASCPT Annual Meeting (March 2009) 

- American Society for Clinical Oncology (ASCO) Young Investigator Award (2009) 

- awarded NIH/NCI F32 CA136123 (11/2009) 

- received Translational Breast Cancer Research Consortium (TBCRC) Award, 2009 

- awarded AACR Future Leaders Award, 2010 

- Current Position: Instructor of Medicine, University of Chicago 

Navin Pinto, MD (2009 – present) 

-recipient of ASCO Young Investigator Award, 2010 

-recipient of St. Baldrick's Fellowship, 2010 

Uchenna Okagbue Njiaju, MD (2010 to present) 

Hematology/Oncology Fellows 

Brian Mitchell, MD, (1990 – 1992) 

-Current position: Hematology/Oncology 

Associates of Virginia, Ltd. 

Sonali Smith, MD, (1999 – 2001) 

-Current position: Associate Professor, Section of Hematology/Oncology, 

University of Chicago 

Brian Weiss, MD, (1999 – 2001) 

-co-mentor with Dr. Kevin Shannon at UCSF 

-recipient of KO8 award, 

-Current position: Assistant Professor, University of Cincinnati (effective July, 

2003) 

University of Chicago: 

Graduate Students‘ PhD. Advisor 

Ryan Hansen, Committee on Cancer Biology, University of Chicago, PhD advisor, 

-Completed Thesis 9/06 

-chosen for best poster presentation at Cancer Biology Retreat, 2004 

-recipient of Doolittle Travel Award, 2005 

-recipient of Woman‘s Board Travel Award, 2005 

-recipient of Committee on Cancer Biology Travel Award, 2006 

Sunita Shukla, Department of Human Genetics, 

-completed thesis 11/07 

-chosen to present a platform presentation at the CSHL Meeting, NY, 2004 

-chosen to present at symposium at the ASCPT Meeting, Orlando, FL, 2005 

-recipient of Presidential Award at ASCPT, 2005 

-recipient of Doolittle Travel Award, 2005 and 2006 

-recipient of Woman‘s Board Travel Award, 2005, 2006 

-chosen to present research at American Society of Human Genetics, 

Salt Lake City, UT, 2005 

-chosen for oral symposium presentation at AACR, 2006 

-selected to attend the first annual NIH Graduate Student Research Festival, 2006 

-recipient of Elaine Ehrman Graduate Travel Award 

5


-recipient of Abbott Laboratories Fellowship, 2007 

Cara Rabik, MD-PhD Student 

-completed thesis 6/08 


-recipient of Woman‘s Board Travel Award, 2006 

-recipient of Wellesley Graduate Fellowship, 2006 


-recipient of University of Chicago Leon O. Jacobson Basic Science Prize, for the 

most meritorious basic science research performed by an MD-PhD, 2010 

Amy Stark, Department of Human Genetic 

-NSF Graduate Research Fellowship Honorable mention (2007, 2008) 

- Doolittle Travel Award to attend ASHG (2008) 

- Graduate Student Awardee for the Lindau Meeting of Nobel Laureates in Lindau, 

Germany, 2010 

- Awardee of Robert-Bosch-Stiftung Fellowship for Lindau Fellows to 

attend Euroscience 2010 

-Chosen for Nature video of Lindau experience 

Visiting Graduate Student 

- Kotila Olayinka Adejoke (MacArthur Foundation Academic Staff Training and 

Development Grant for 6 month training in lab) 

Post-doctoral Fellows 

Sandip Roy, PhD, (1994 – 1997), 

-Current position: Associate Director/Senior Lead Pharmacokineticist, Novartis, East 

Hanover, NJ 

Lina Long, PhD, (1997 – 2001), 

-Current position: Research Chemist, SC Johnson Inc. (Racine, Wisconsin) 

Yingna Cai, PhD, (1997 – 2001), 

-recipient of Cure for Lymphoma Foundation 

-Current position: Scientist, Respiratory Disease/Rheumatoid Arthritis, Aventis, NJ 

Michael Wu, PhD, (1997 – 2004) 

-recipient of GI Training Grant Fellowship, 

-Current position: Senior Scientist, Southern Biotechnology Associates, Inc., 

Melissa Fishel, PhD, (2001 – 2004) 

-recipient of Cancer Biology Training Grant Fellowship, 

-Current Position: Research Associate, Indiana University 

Shiwei Duan, PhD, (2005-2009) 

-Current position: Senior Research Fellow, Singapore Institute for Clinical Sciences 

-recipient of Cancer Biology Training Grant Fellowship in 2005 and 2006 


Wei Zhang, PhD, (2005-2010) 

-Current Position Assistant Professor, Dept of Pediatrics, UIC 

Shuangli Mi, PhD, (2008-2009) 

-Current Position: Faculty in Beijing, China 

-chosen to present at CSHL Pharmacogenetics Meetings, November 2008 

Marleen Welsh (2009-2010) 

- received DOD postdoctoral fellowship 

Heather Wheeler (2010-present) 

Yujia Wen (2010-present) 

6

Howard Hughes Summer Fellowship Students 

Elizabeth A. Ferries (1996) 

Undergraduate Thesis Honors Committee 

Kristin Anderson (2002) 

Undergraduate Thesis Honors Student 

Shan Wong (2009-present) 

Undergraduate Extramural Research Placement 

Maria Chidiamara Njoku, School of Pharmacy, London, England (Spring Quarter, 

2005) 

Medical Student Summer Research Training Program 

David Au (1990) 

Paul Helft (Received ACS outstanding medical student award for his summer 

project) (1994) 

Bruce Kuang-Huay Tan (Received honorable mention from Biological Science 

Division for his summer project; received Howard Hughes Medical Student 

training fellowship) (2000) 

Jason Elinoff (Received Outstanding Basic Science award from Biological Science 

Division for his summer project; received Howard Hughes Medical Student 

training fellowship) (2000) 

Samantha Feinberg (2001) 

Ben Remo (2001) 

MSTP Cluster Co-Leader (2002) 

MSTP Cluster Co-Leader (2003) 

Matthew Kalscheur (2005) 

Medical Student Reading Course 

Chester Drum (Spring Quarter, 2001) 

Cara Rabik (Spring Quarter, 2004) 

Matthew Kalscheur (Spring Quarter, 2005) 

Summer Research Opportunities for Undergraduate Students 

Jia Yang (1994) 

Shari Bass (1998) 

Iva Huljev (2005) 

Tanishke Armbrister (2008) 

ACM Minority Fellowship Program 

Nazeer Khan (1993) 

Pritzker School of Medicine Experience in Research 

Yarden Fraiman (Best presentation in the Summer Research Forum at U of C (2008) 

High School Research Mentoring Programs 

Tirzah Mitchell (won district/city/state Science Fair (1990) 

Willie Tran: ACS, IL – High School Research Program; (Summer, 2003) 

Shaji Khan: ACS, IL – High School Research Program; (Summer, 2004) 

7

-Winner of Chicago City-Wide Science Fair 

Jack Chen: Lake Forest Leadership Program (2004) 

Cindy Wang: Illinois Math and Science Academy (Academic Year, 2004 – 

2005) 

Michael Jackson: ACS, IL – High School Research Program; (Summer, 2005) 

Kenneth Burges, ACS, IL – High School Research Program; (Summer, 2006) 

Taylor Erickson, Ignatius High School, shadowed for week (Summer, 2010) 

Gabriella Lock, Ignatius High School, shadowed for week (Summer, 2010) 

Editorial Board 

Molecular Cancer Therapeutics 

Current Pharmacogenomics (North American Regional Editor 2006, 2007) 

Journal Reviewer 

Nature Genetics 

Human Molecular Genetics 

Pharmacological Reviews 

Journal of Cellular and Molecular Medicine 

American Journal Human Genetics 

PLos Genetics 

Current Pharmacogenomics 

Pharmacogenetics and Genomics 

The Pharmacogenomics Journal 

Nature Reviews Cancer 

Journal of Pharmacology and Experimental Therapeutics 

Cancer Research 

Leukemia and Lymphoma 

Journal of National Cancer Institute 

Cancer Chemotherapy and Pharmacology 

Clinical Cancer Research 

Genes, Chromosomes and Cancer 

Oncology Research 

British Journal of Cancer 

International Journal of Cancer 

Life Sciences Journal 

Oncology 

Nucleic Acids Research 

Canadian Journal of Physiology and Pharmacology 

Grant Reviews/Study Sections 

NCI Cancer Health Disparities Study Section, March, 2010 

Reviewer for Population Genetics Analysis Program, NIAID, NIH, Nov, 2009. 

Reviewer for NIH Challenge, Grand Opportunity and Administrative Supplements, June-Aug, 

2009 

University of Chicago Fentress Award Review, 2009 

University of Chicago Cancer Biology Postdoc Awardees, 2006-2009 

UCCRC Breast SPORE Pilot projects and developmental awards, 2007-present 

UCCRC Program Specific Projects, 2008-present 

AACR Basic Cancer Research Fellowships Scientific Review Committee, 2009 

NIH/NCI PO1 Reviews October, 2008 

Genetic Epidemiology Grant Reviews, UCCRC, 2007 

8

Cancer Research Campaign- UK Drug Development Reviews, August, 2007. 

DT Study Section Full Member, January, 2003 to June, 2006, ad hoc October, 2006 (ET-2 

prior to October, 2003) 

Cancer Research-UK, Manchester, Carcinogenesis site visit March 2003 

NIH ET-2 Special Review Session, May, 1997; April, 1998; August, 1998; 

December,1999; April, 2000; January, 2001; January, 2002. 

NIH, ET-2 Study Section; Ad hoc; October, 1992; June, 1993; October, 2000; June, 

2001; June, 2002. 

Leukemia Research Foundation, Medical Advisory Board; 1996-2004. 

Cancer Research Campaign, London, ad hoc June 2000; November, 2001; October 

2006 

NIH, SBIR Grant Review, October, 1998 

Department of Defense, Prostate Cancer Review Panel, January, 1998 

Department of Defense Breast Cancer Review Panel, 11/95; 9/9 

ACS, Illinois Division Medical Advisory Board; 1996 to 2000 

Ohio Cancer Research Reviews; May, 1997 

Medical Research Council of Canada Grant Review; November, 1996 

NIH, NCNPDDG Grant Reviews; March, 1995 

NIH, Program Project Review; October, 1994; June, 1995 

Volunteer Grant Application Mentor, Biological Science Division, University of Chicago, 2005 

External Advisory Committees 

Scientific Advisory Board to NIGMS Human Genetic Cell Repository at the Coriell 

Institute for Medical Research, Camdem, NJ (http://www.coriell.org/) (January, 

2006-2009) 

Pharmacogenetics Research Network White Papers Task Force, Co-Chair (2006- 

2008) 

AACR Program Committee Member for 2008 meeting 

AACR Education Committee Member for 2009 and 2010 meeting, Chairperson of 

Educational Session on Pharmacogenomics 

ACS, IL Research Strategic Planning and Quality Review Committee, 2010 

Board of Directors 

ACS, IL October, 2001 to 2010 

Meetings/Symposium Organized 

Organizing Committee of the 8 th International Workshop on Pharmacodynamics of 

Anticancer Agents in Hokane, Japan, October, 2010 

Chairperson, University of Chicago Cancer Center Symposium entitled ―Personalized 

Cancer Therapies‖, Oct, 2010 

Chairperson, University of Chicago Committee of Genetics Symposium entitled ―Translating 

Genomics into Personalized Therapeutics‖, March, 2010 

Organizing Committee, 2008 International Conference on Pharmacogenomics in 

Busan, Korea, April 2008 

Chairperson of the 7 th International Workshop on Pharmacodynamics of Anticancer 

Agents in Costa Rica, September 2007 

Formal Research Seminars Given 

9

March, 2011 Invited to speak at University of Pittsburg 25th Anniversary Cancer 

Genomics and the Impact of Next Generation Sequencing Symposia 

Feb, 2011 Invited to speak at Personalized Cancer Medicine: towards 

individualized cancer treatment symposium, Singapore 

Dec, 2010 Invited to speak at CALGB, Chicago, IL 

Dec, 2010 Invited to speak at Midwestern University, Downers Grove, IL 

Oct, 2010 Invited speaker at NCI Cancer Pharmacogenomics Workshop, 

Bethesda, MD 

Sept, 2010 Invited to speak at Next Generation Sequencing meeting, Providence, 

RI 

Sept, 2010 Invited as panel discussant for University of Chicago Beijing opening; 

(unable to attend due to motor vehicle accident) 

Sept, 2010 Invited speaker for 19th Annual Beaumont Hospitals Molecular 

Pathology Symposium, Troy Michigan 

August, 2010 Invited keynote speaker to 9th International Conference of Asian Clinical 

Oncology Society, Gifu, Japan 

June, 2010 Invited speaker to Colorado State University, Fort Collins, CO 

May, 2010 Speaker for 2010 Breast SPORE Roundtable Meeting at Gaylord 

Convention Center, Washington, DC 

May, 2010 Invited speaker for Cancer Center Seminar Series at UT-Southwestern, 

Dallas TX 

April, 2010 Invited speaker for ASPET Symposium on Integrating Genetics, 

Genomics and Pharmacology, Anaheim, CA 

April, 2010 Chairperson and speaker at Educational Session on 

Pharmacogenomics Session at AACR, Washington, DC 

February, 2010 Speaker for University of Chicago Breast SPORE retreat 

February, 2010 Invited speaker for 3 rd International Scientific Forum by Yokohama City 

University, Yokohama, Japan 

January, 2010 Speaker for PGRN-RIPs, video conferenced to Pharmacogenetic 

Research Network 

September, 2009 Invited speaker at International Meeting on Human Genome Variation 

meeting, Tallinn, Estonia 

June, 2009 Invited speaker at Canadian Pharmacogenomics Network for Drug 

Safety, Vancouver, BC, Canada 

May, 2009 Invited speaker for International Testicular Cancer Survivor Workshop, 

Rochester, NY 

April, 2009 Chairperson and speaker at Educational Session on 

Pharmacogenomics Session at AACR, Denver, CO 

January, 2009 Invited speaker at University of California, San Diego 

November, 2008 Invited to attend NCI-Translational Meeting, Bethesda, MD 

October, 2008 Invited speaker for 15 th North American ISSX Meeting, San Diego, CA 

September, 2008 Invited to speak at Personalized Medicine Seminar Series, Indiana 

University, Indianapolis, IN 

July, 2008 Presented at the IXth World Conference on Clinical 

Pharmacology and Therapeutics (CPT2008), Quebec, Canada 

June, 2008 Invited speaker GLC-ASPET Pharmacogenomics Symposium, Chicago, 

IL 

June, 2008 Invited speaker for Affymetrix, New York, Bethesda and Houston 

April, 2008 Invited speaker for the 2008 International Conference on 

Pharmacogenomics, Busan, Korea 

April, 2008 Invited speaker for ASCPT, Orlando, FL 

10

March, 2008 Invited speaker Genetics of Rare Disease Mtg, Asilomar, CA 

February, 2008 Keynote speaker for Affymetrix Core Lab Mtg, New Orleans, LA 

November, 2007 Breast Cancer SPORE Retreat, Chicago, IL 

November, 2007 University of Chicago Molecular Biosciences Retreat, Galena, IL. 

November, 2007 AACR Translational Medicine meeting in Singapore 

September, 2007 7 th International Workshop on Pharmacodynamics of Anticancer 

Agents in Costa Rica 

September, 2007 Presented for PGRN-RIPS Seminar, Chicago, IL. 

August, 2007 NIH GEI Workshop, Rockville, MD 

July, 2007 15th Annual SPORE meeting, Baltimore, MD 

June, 2007 MGMT Meeting, Mainz, Germany 

January, 2007 Breast Cancer SPORE meeting, University of Chicago, 

Chicago, IL. 

December, 2006 Ordway Cancer Center, Albany, NY 

November, 2006 Invited to give 2 plenary session presentations at NCI – EORTC 

Meeting, Prague, Czechoslovakia (Alkyltransferase Inhibitors; Unbiased 

Approaches to Identifying Genetic Determinants of Anticancer Toxicity) 

August, 2006 Lutheran General, Hematology Oncology, Park Ridge, IL 

July, 2006 Department of Clinical Pharmacology, Vanderbilt University, Nashville, 

TN 

February, 2006 Department of Medicine, University of Chicago, Chicago, IL 

September, 2005 Head and Neck Cancer Retreat, Chicago, IL 

September, 2005 Thoracic Oncology Retreat, Chicago, IL 

August, 2005 International MGMT Meeting at Keele Conference Center in England 

May, 2005 Friday Research Conference, University of Chicago, Chicago, IL 

March, 2005 Purdue University, West Lafayette, IN 

December, 2004 Indiana University, Indianapolis, IN 

November, 2004 University of Newcastle, England 

November, 2004 6 th International Workshop on Pharmacodynamics of Anticancer Agents, 

Venice, Italy 

August, 2004 Duke University, Durham, NC 

June, 2004 Thoracic Oncology Retreat, Chicago, IL 

September, 2003 University of Pittsburgh, Pittsburgh, PA 

July, 2003 Educational Session, AACR, Washington, DC 

April, 2003 UCCRC, University of Chicago, Chicago, IL 

March, 2003 University College London, England 

March, 2003 University of Newcastle, England 

February, 2003 University of Illinois, Peoria, IL 

June, 2002 Georgetown University, Washington DC 

February, 2002 Temozolomide Investigators meeting, Carlsbad, CA 

January, 2002 Access Oncology, Flushing, NY 

November, 2001 Westinghouse Science Honors Program, Pittsburgh, PA 

June, 2001 Midwest DNA Repair Symposium, Indiana University, Indianapolis, IN 

May, 2001 Chicago Cancer Experimental Therapeutics Group, Northwestern 

University 

March, 2001 Section of Hem-Onc., University of Illinois, Chicago, IL 

March, 2001 Department of Biochemistry and Molecular Biology, Indiana University 

(annual graduate student invitee) 

January, 2001 Clinical Research Training Program, University of Chicago 

December, 1999 International Conference on Gene Therapy of Cancer, San Diego, CA 

September, 1999 Department of Pharmaceutics, University of Illinois, Chicago, IL 

11

May, 1999 Translational Opportunities In/From DNA Repair Research Meeting, 

Chicago, IL 

October, 1998 Pediatric Oncology Group Meeting, Brain Tumor Session and New 

Agent Group Meeting, Chicago, IL 

October, 1998 Department of Pharmacology, St. Jude, Memphis, TN 

August, 1998 4 th International Workshop on the Pharmacodynamics of Anticancer 

Agents, Dunkeld, Scotland 

July, 1998 Cancer Center, Indiana University, Indianapolis, IN 

June, 1998 Department of Medicine, Vanderbilt University, Nashville, TN 

February, 1998 Keynote Speaker, University of Nebraska Cancer Center Drug 

Discovery Retreat, Omaho, NE 

November, 1997 Cancer Center, University of Illinois, Chicago, IL 

September, 1997 Department of Biology, Calvin College, Grand Rapids, MI 

September, 1997 Department of Biology, Hope College, Holland, MI 

May, 1997 Frontier in Cancer Research, University of Chicago, Chicago, IL 

November, 1995 CALGB PET Committee, Dallas, TX 

February, 1994 Department of Radiation Biology, Argonne National Laboratories 

October, 1993 Department of Medicine, University of Chicago, Chicago, IL 

January, 1993 Department of Human Oncology, University of Wisconsin 

October, 1992 Cancer Center, Michigan State University 

January, 1992 Department of Pediatrics, Duke University 

December, 1989 Department of Pharmacology, University of Pittsburgh 

March, 1989 Department of Biology, Millersville University 

March, 1989 Department of Pharmacology, Northwestern University 

January, 1989 Department of Environmental Health, University of Cincinnati 

December, 1988 Department of Pharmacology, Wayne State University 

July, 1988 Department of Human Oncology, University of Wisconsin 

July, 1987 Department of Pharmacology, Loyola University 

April, 1986 Department of Radiobiology, The Ohio State University 

January, 1986 Gordon Conference on DNA Repair, Santa Barbara, CA 

November, 1985 Department of Molecular Genetics and Cell Biology, The University of 

Chicago, Chicago, IL 

June, 1985 Repair of DNA Lesions Introduced by N-Nitroso compounds, University 

of Tromso, Tromso, Norway 

Invited Presentations but unable to attend 

Feb, 2008 Riken Institute, Japan 

Informal Seminars/Lay Education 

June, 2010 ACS, IL High School Summer Program, Chicago 

June, 2009 ACS, IL High School Summer Program "Cancer Research", Chicago, IL 

June, 2009 ACS, IL Presented at Planned Giving meeting, Glenview, IL 

Oct, 2008 ACS, IL Presented at Planned Giving Meeting, Chicago, IL 

Sept, 2008 ACS, IL Presented talk at Distinguished Giving Meeting, Addison, IL 

June, 2008 ACS,IL High School Summer Program "Cancer at the Molecular Level", 

Chicago, IL 

Oct, 2007 DNA isolation for 6 th , 7 th , 8 th grade at Ascension School, Oak 

Park, IL 

July, 2007 ACS, IL High School Program ―Cancer- At the Cellular and 

Molecular Level", Chicago, IL. 

April, 2007 ACS, IL Tinley Park Division, Chicago, IL 

12

Oct, 2006 Ascension School, 6 th Graders, Oak Park, IL 

Aug, 2006 ACS, IL Making Strides Against Breast Cancer, Chicago, IL 

July, 2006 ACS, IL High School Research Program 

May, 2006 Ascension School, 5 th and 6 th graders, Oak Park, IL 

Nov, 2005 Ascension School, 5 th and 6 th graders, Oak Park, IL 

Oct, 2005 ACS, IL – Annual Meeting 

Sept, 2005 Berwyn Public School, Berwyn, IL 

July, 2005 ACS, IL – Relay for Life, North Riverside, IL 

July, 2005 ACS, IL – Board of Directors Meeting, Chicago, IL 

July, 2005 Hem/Onc Summer Research Program 

June, 2005 ACS, IL – Borg-Warner, Bellwood, IL 

June, 2005 ACS, IL – High School Program, Chicago, IL 

June, 2005 Ascension School, Cancer, Oak Park, IL 

March, 2005 ACS, IL – Board of Directors Meeting, Chicago, IL 

November, 2004 ACS, IL – Giving at Work Program, Hyde Park, IL 

October, 2004 ACS, IL – Board of Directors Meeting, Oak Brook, IL 

October, 2004 Ascension School, Mammalian Cells and Tissues, Oak Park, IL 

August, 2004 ACS, IL – 2004 Making Strides Against Breast Cancer Kickoff 

Breakfast, Chicago, IL 

June, 2004 ACS, IL – Cancer Research, Chicago, IL 

June, 2004 Summer Student Seminar Series, University of Chicago, Chicago, 

IL 

March, 2004 ACS, IL – Cancer Research, Maywood, IL 

March, 2004 ACS, IL – Cancer Research, Brookfield, IL 

February, 2004 ACS, IL – Impact of Human Genome Project on Cancer 

Research, Northbrook, IL 

January, 2004 University of Chicago, Human Genome Project, Stuart, FL 

January, 2004 University of Chicago, Human Genome Project, Chicago, IL 

January, 2004 ACS, IL – Discoveries in Cancer Research, Crystal Lake, IL 

November, 2003 ACS, IL – Anticancer Drug Development, LaGrange, IL 

November, 2003 Ascension School - Animals in Research, Oak Park, IL 

November, 2003 UC Dean‘s Visiting Committee, Gleecher Center, Chicago, IL 

October, 2003 ACS, IL – DNA Repair, Frankfort, IL 

August, 2003 ACS, IL - Cancer Research, Training Session for new employees, 

Chicago, IL 

August, 2003 ACS, IL - New Discoveries in Breast Cancer, Rockford, IL 

May, 2003 ACS, IL – Discoveries in Cancer Research, Jacksonville, IL 

May, 2003 ACS, IL, Research Tours, University of Chicago, Chicago, IL 

May, 2003 Keynote Speaker, Countdown to a Cure, Royal Melbourne 

Country Club, Long Grove, IL 

December, 2002 ACS, IL – Employee Initiation, Cancer Research, Chicago, IL 

August, 2002 ACS, IL – Significant Discoveries in Cancer Research, Chicago 

April, 2002 UCCRC Board of Directors Meetings – Improving chemotherapy 

by inactivating DNA repair, Chicago, IL 

April, 2002 ACS, IL - New Chemotherapeutic Drugs, Galena, IL 

March, 2002 St. Bartholomew‘s School, Cancer, Chicago, IL 

December, 2001 ACS, IL - Cancer Drug Development, Annual Meeting, 

Oak Brook, IL 

August, 2001 ACS, IL - Cancer: How it Develops, Training Session for new 

employees, Chicago, IL 

13

August, 2001 ACS, IL - Making Strides Against Breast Cancer, Chicago, IL 

June, 2001 ACS, IL - Relay for Life, Park Ridge, IL 

June, 2001 ACS, IL - Arlington Race Track, Arlington Heights, IL 

March, 2001 ACS, IL - Walk & Roll Kick-off, Chicago, IL 

Jan-Feb, 2001 ACS, IL - Relay for Life, Geneva, IL and Highland Park, IL 

June-July, 2000 ACS, IL - Relay for Life, Havana, IL and Quincy, IL 

March, 2000 ACS, IL - Walk & Roll, Chicago, IL 

July, 1999 ACS, IL - Relay for Life, Mason County, IL 

March, 1998 ACS, IL - Kick-Off Dinner, Springfield, IL 

Community Service 

2008-present Initiated ―Manicure Ministry‖ with Old St. Pat‘s, organize and perform 

monthly manicures for women at House of Mary and Joseph Shelter 

2001 to 2010 Organized University of Chicago ACS, IL Walk/Roll Team (most years) 

2006 ACS, IL, Celebration on the Hill Ambassador 

2005-present University of Dayton Christmas Off-Campus for Association House, 

Chicago, IL. (2009 served as chairperson) 

2005-2010 ACS, IL, Served on Distinguished Giving Cabinet 

2003-2010 ACS, IL, Serve on committee to initiate and run high school research 

internship 

2005-present Help organize Christmas gifts for approx. 20 children at Tabetha House 

2003-2005 Tabetha House (prepare dinner for 80 women and children – once per 

month) 

2002 ACS, IL, Served on 50 th Anniversary of Research Gala Organizing 

Committee 

2000-2008 Children‘s Friendship Project for Northern Ireland – U.S. Representative 

1999 Children‘s Friendship Project for Northern Ireland – Host Family 

Patents Awarded 

U.S. Patents and Applications 

1. Moschel, R. C., Dolan, M. E., and Pegg, A. E.: O 6 -benzylated guanine, guanosine and 2'deoxyguanosine 

compounds possessing O 6 -alkylguanine-DNA alkyltransferase depleting 

activity. U.S. Patent 5,352,669 issued October 4, 1994. 

2. Moschel, R. C., Pegg, A. E., Dolan, M. E., and Chae, M.-Y.: Substituted O 6 -benzylguanines 

and 6(4)-benzyloxypyrimidines. U.S. Patent 5,525,606 issued June 11, 1996. 

3. Moschel, R. C., Dolan, M. E., Pegg, A. E., McDougall, M. G., and Chae, M.-Y.: O 6 - 

substituted guanine compositions and methods for depleting O6-alkylguanine-DNA 

alkyltransferase. U.S. Patent 5,691,307 issued November 25, 1997. 

4. Moschel, R. C., Pegg, A. E., Dolan, M. E., and Chae, M.-Y.: Substituted benzyloxypyrimidines 

and their inactivation of O 6 -alkylguanine-DNA alkyltransferase. U.S. Patent 

5,753,668 issued May 19, 1998. 

5. Dolan, M. E., Frydman, B.J., Witiak, D. T., Neder, K. M., and Marton, L. J.: 4-Substituted-1,2naphthoquinones 

and Their Use in the Inhibition of Neoplastic Cell Growth. U.S. Patent 

5,883,270 issued March 16, 1999. 

14


and 6(4)-benzyloxypyrimidines. U.S. Patent 5,916,894 issued June 29, 1999. 

7. Moschel, R. C., Chae, M.-Y., Dolan, M. E., and Pegg, A. E.: Substituted O 6 -benzylguanines, 

compositions and methods of using same. U.S. Patent 5,958,932 issued September 28, 

1999. 

8. Moschel, R. C., Pauly, G. T., Pegg, A. E., and Dolan, M. E.: Oligodeoxyribonucleotides 

comprising O 6 -benzylguanines and their use. U.S. Patent 6,060,458 issued May 9, 2000. 

9. Moschel, R. C., Pegg, A. E., Dolan, M. E, and Chae, M.-Y.: Substituted O 6 -benzyl-8-azaguanines 

and 6(4)-benzyloxypyrimidines. U.S. Patent 6,172,070 issued January 9, 2001. 


and 6(4)-benzyloxypyrimidines. U.S. Patent 6,303,604 issued October 16, 2001. 

11. Moschel, R. C., Chae, M.-Y., Dolan, M. E., and Pegg, A. E.: Substituted O 6 -benzylguanines 

and 6(4)-benzyloxypyrimidines. U.S. Patent 6,333,331, December 25, 2001. 

12. Moschel, R. C., Chae, M.-Y., Dolan, M. E., and Pegg, A. E.: Substituted O 6 -benzyl-8-azaguanines. 

U.S. Patent 6,436,945 issued August 20, 2002. 

13. Frydman, B.J., Witiak, D.T., Marton, L.J., Neder, K.M. and Dolan, M.E.: Novel 4-substituted- 

1,2-naphthoquinones, pharmaceutical unit dosage forms containing 4-substituted-1, 2naphthoquinones, 

and uses of 4-substituted-1, 2-naphthoquinones to inhibit the growth of 

cancer cells are disclosed. U.S. Patent 5,977,187. 

Current Grant Support 

NIH/NHGRI HG005773-01 ―Rare Variants and Complex Human Phenotypes‖ 4/1/10-3/31/12, PI: 

N.J. Cox, co-I: M.E. Dolan, 10% effort, TDC $299,951/yr 

NIH/NCI R01CA136765 “Genetic determinants associated with pemetrexed response and toxicity‖ 

7/1/09-6/30/14, PI: M. E. Dolan, 10% effort, TDC - $250,000/yr 

NIH/NCI R21CA139278-01 ―Incorporation of microRNA expression in pharmacogenetic prediction 

models‖ 3/1/09-2/28/11, co-PI‘s: P.I. M.E. Dolan and R.S. Huang, 5% effort, TDC -$120,000/yr 

NIGMS U01 GM61393 ―Pharmacogenetics of Anticancer Agents Research Group‖ 7/16/10-6/30/15, 

co-P.I.’s: M. E. Dolan, Nancy J. Cox, and M. J. Ratain; 23% effort, TDC - $1,434,651/yr 

NIH/NCI P50 CA125183 ―University of Chicago Breast SPORE‖ 11/1/06-10/31/11, P.I.: F.I. 

Olopade; ―Identifying population specific variants important in toxicity to breast cancer 

chemotherapy‖ Project 4 PI: M.E. Dolan, 10% effort, and Career Development Program , co-P.I. 

M.E. Dolan, 2% effort; TDC- $194,660/yr for Project 4; TDC- $58,072 for Career Development 

Program. 

NIH/NCI 2 U01 CA69852-04, ―Phase I Clinical Trials of Anti-Cancer Agents‖ 3/01/03–2/28/08, P.I.: 

M. J. Ratain, co-Investigator: M. E. Dolan, 5% effort, salary support only. 

15

NIH/NCI P30 CA14599 ―UCCRC-Cancer Center Support Grant‖ 4/1/02-3/31/12, P.I.: M. LeBeau, 

co-Leader of the Clinical and Experimental Therapeutics Program, M. E. Dolan (8% effort). 

Leukemia & Lymphoma Society Specialized Center of Research ―Mechanisms of Treatment 

Responsiveness and Resistance in Myeloid Malignancies‖ 10/1/03-09/30/08, P.I. S. Lowe, Director 

of the Pharmacokinetic/Pharmacodynamic Co-Investigator: M.E. Dolan. (5% effort), TDC - 

$40,000. 

NIH/NCI RO1 CA 16783 ―Pharmacology of Cyclophosphamide and Other Alkylators‖ 4/1/05- 

3/31/10 P.I. Colvin (Subcontract PI – M.E. Dolan). 

UCCRC Pilot Project Awards (PI: M. E. Dolan): 

―Incorporating Resequencing Datasets in Pharmacogenomic Discovery‖ 4/1/09-3/31/10, $35,000 

―Incorporation of miRNAs as Predictors of Cancer Therapy Responses‖ 1/1/09-12/31/09, $30,000 

―Incorporation of microRNA studies in Pharmacogenomic Modeling‖ 8/14/08-8/15/09, $40,000 

―Investigation of Genetic Determinants of Capecitabine-Related Chemotherapy Toxicity‖ 9/1/09- 

8/31/10, $32,322 

―Pharmacogenomic studies related to t-AML‖ 8/1/09-7/31/10, $125,000 

Previous Grant Support 

NIH/NCI R29 CA47228, ―Modulation of Alkyltransferase to enhance chemotherapy‖ 4/8/89–3/31/94, 

P.I.: M.E. Dolan, 50% effort, TDC - $293,844. 

NIH/NCI RO1 CA81485 ―Role of DNA repair in protecting against secondary leukemias‖ 4/1/99- 

3/31/10, P.I: M. E. Dolan, 20% effort, TDC - $601,650. 

NIH/NCI U19 CA57725, ―Inhibition of DNA Repair to Enhance Chemotherapy‖ 7/1/92–7/31/01, P.I.: 

A. E. Pegg; Project 2 and Core C P.I.: M.E. Dolan, 10% effort, TDC - $718,808. 

NIH/NCI RO3, CA67098 ―Clinical and Biochemical Analysis of O 6 -benzylguanine‖ 4/15/95–3/31/97, 

P.I.: M.E. Dolan (received a priority score of 115), 20% effort, TDC - $100,000. 

NIH/NCI RO1 CA69538, ―In vivo Detection of Radiation Induced Free Radicals‖ 7/1/96–6/30/00, 

P.I.: Howard Halpern, co-P.I.: M.E. Dolan, 5% effort, salary support only. 

NIH/NCI RO1 CA71627, ―Selective Depletion of Alkyltransferase in Tumor Cells‖ 8/1/96–7/31/00, 

P.I.: M.E. Dolan, 40% effort, TDC - $479,888. 

NIDR/NCI P50 DE/CA1192, ―Carcinogenesis and Novel Therapeutics in Oral Cancer‖ 9/30/96-- 

7/31/02, P.I.: E.E. Vokes; Project 2 P.I.: M.E. Dolan, 15% effort, TDC - $472,750. 

NIH/NCI 2 U01 CA69852-04, ―Phase I Clinical Trials of Anti-Cancer Agents‖ 3/1/98–2/28/03, P.I.: 

M. J. Ratain, co-P.I. M. E. Dolan, 7.5% effort, salary support only. 

Pilot projects: UCCRC funds awarded for 2 projects: ―Electrochemical detection of oxidative 

damage and anticancer agents‖ P.I.: M. E. Dolan, TDC - $25,000 and Selective protection of bone 

marrow cells from O 6 -benzylguanine and BCNU. P.I.: M. E. Dolan, TDC - $35,000 

NIH/NCI P30 CA14599 ―UCCRC-Cancer Center Support Grant‖ 4/1/02-6/30/09, P.I.: M. LeBeau, 

P.I. for the Pharmacology Core Facility, M.E. Dolan, 10% effort, TDC for Core $246,353. 

16

DOD BC087674, Postdoctoral; "Pharmacogenetic Discovery for Breast Cancer Agents" 9/15/09 – 

3/4/10, PI: M.M. Welsh, TDC - $351,000 (Sponsor: M. E. Dolan) 

NIGMS U01 GM61393 ―Pharmacogenetics of Anticancer Agents Research Group‖ 4/1/00-3/31/10, 

P.I.: M. J. Ratain; Project 2, 5 and Core, P.I. M.E. Dolan, 27.5% effort, TDC - $499,102 for Project 

2; TDC - $288,658 for Project 5; TDC - $194,799 for Core. 

Publications - Original Articles 

1. Weinkam, R.J., Dolan, M.E. An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the 

cellular level. J. Med. Chem., 26:1656-1659, 1983. 

2. Dolan, M.E., Scicchitano, D., Singer, B., Pegg, A.E. Comparison of repair of methylated 

pyrimidines in poly(dT) by extracts from rat liver and Escherichia coli. Biochim. Biophys. Res. 

Commun., 123:324-330, 1984. 

3. Pegg, A.E., Scicchitano, D., Dolan, M.E. Comparison of the rates of repair of O 6 - 

alkylguanines in DNA by rat liver and bacterial O 6 -alkylguanine-DNA alkyltransferase. Cancer 

Res., 44:3806-3811, 1984. 

4. Domoradzki, J., Pegg, A.E., Dolan, M.E., Maher, V.M., McCormick, J.J. Correlation between 

O 6 -methylguanine-DNA methyltransferase activity and resistance of human cells to the 

cytotoxic and mutagenic effect of N-methyl-N'-nitro-N-nitrosoguanidine. Carcinogenesis, 

5:1641-1647, 1984. 

5. Morimoto, K., Dolan, M.E., Scicchitano, D., Pegg, A.E. Repair of O 6 -propylguanine and O 6 - 

butylguanine in DNA by O 6 -alkylguanine-DNA alkyltransferases from rat liver and E. coli. 

Carcinogenesis, 6:1027-1031, 1985. 

6. Pegg, A.E., Dolan, M.E. , Scicchitano, D., Morimoto, K. Studies of the repair of O 6 - 

alkylguanine and O 4 -alkylthymine in DNA by alkyltransferases from mammalian cells and 

bacteria. Environmental Health Perspectives, 62:109-114, 1985. 

7. Dolan, M.E., Morimoto, K., Pegg, A.E. Reduction of O 6 -alkylguanine-DNA alkyltransferase 

activity in HeLa cells treated with O 6 -alkylguanines. Cancer Res., 45:6413-6417, 1985. 

8. Dolan, M.E., Pegg, A.E. Extent of formation of O 4 -methylthymidine in calf thymus DNA 

methylated by N-methyl-N-nitrosourea and lack of repair of this product by rat liver O 6 - 

alkylguanine-DNA-alkyltransferase. Carcinogenesis, 6:1611-1614, 1985. 

9. Domoradzki, J., Pegg, A.E., Dolan, M.E., Maher, V.M., McCormick, J.J. Depletion of O 6 - 

methylguanine-DNA methyltransferase in human fibroblasts increases the mutagenic 

response to N-methyl-N'-nitro-N-nitrosoguanidine. Carcinogenesis, 6:1823-1826, 1985. 

10. Dolan, M.E., Corsico, C.D., Pegg, A.E. Exposure of HeLa cells to O 6 -alkylguanines increases 

sensitivity to the cytotoxic effects of alkylating agents. Biochem. Biophys. Res. Commun., 

132:178-185, 1985. 

11. Dolan, M.E., Young, G.S., Pegg, A.E. The effect of O 6 -alkylguanine pretreatment on the 

sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents. 

Cancer Res., 46:4500-4504, 1986. 

17

12. Knachel, HC., Owens, SD., Lawrence, SH., Dolan, M.E., Kerby, MC., Salupo, TA. Reactions 

of HCl(g), DCl(g), and HBr(g) with the Adduct Pyrazine-Phosphorus(V) Chloride. Inorganic 

Chemistry, 25:4606, 1986 

13. Dolan, M.E., Oplinger, M., Pegg, A.E. Use of a dodecadeoxy nucleotide to study repair of the 

O 4 -methylthymine lesion. Mutation Res., 193:131-137, 1988. 

14. Dolan, M.E., Scicchitano, D., Pegg, A.E. Use of oligodeoxynucleotides containing O 6 - 

alkylguanine for the assay of O 6 -alkylguanine-DNA alkyltransferase activity. Cancer Res., 

48:1184-1188, 1988. 

15. Pegg, A.E., Morimoto, K., Dolan, M.E. Investigation of the specificity of O 6 -alkylguanine-DNA 

alkyltransferase. Chem. Biol. Interactions., 65:275-281, 1988. 

16. Brent, T.P., Dolan, M.E., Fraenkel-Conrat, H., Hall, J., Karran, P., Laval, F., Margison, G.P., 

Montesano, R., Pegg, A.E., Singer, B., Swenberg, J.A., Yarosh, D.B. A present consensus on 

repair of O-alkylpyrimidines in mammalian cells. Proc. Natl. Acad. Sci., USA, 85:1759-1762, 

1988. 

17. Dolan, M.E., Pegg, A.E., Hora, N.K., Erickson, L.C. Effect of O 6 -methylguanine on DNA 

interstrand cross-link formation by chloroethylnitrosoureas and 2-chloroethyl (methylsulfonyl) 

methanesulfonate. Cancer Res., 48:3603-3606, 1988. 

18. Belinsky, S.A., Dolan, M.E., White, C.M., Maronpot, R.R., Pegg, A.E., Anderson, M.W. Cell 

specific differences in O 6 -methylguanine-DNA methyltransferase activity and removal of O 6 - 

methylguanine in rat pulmonary cells. Carcinogenesis, 9:2053-2058, 1988. 

19. Dolan, M.E., Oplinger, M., Pegg, A.E. Sequence specificity of guanine alkylation and repair. 


20. Weinkam, R.J., Dolan, M.E. Intracellular activation of cytotoxic agents: Kinetic models for 

methylnitrosoureas and N-methyl-N'-nitro-nitrosoguanidine (MNNG) in cell culture. Chemical 

Res. Toxicology, 2:157-161, 1989. 

21. Dolan, M.E., Norbeck L., Hora, N.K., Erickson, L.C., Pegg, A.E. Expression of mammalian 

O 6 -alkylguanine-DNA alkyltransferase in a cell line sensitive to alkylating agents. 


22. Dolan, M.E., Larkin, G.L., English, H.F., Pegg, A.E. Depletion of O 6 -alkylguanine-DNA 

alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by 

treatment with O 6 -methylguanine. Cancer Chemo., Pcol., 25:103-108, 1989. 

23. Dolan, M.E., Moschel, R.C., Pegg A.E. Depletion of mammalian O 6 -alkylguanine-DNA 

alkyltransferase activity by O 6 -benzylguanine provides a means to evaluate the role of this 

protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl. Acad. 

Sci., USA, 87:5368-5372, 1990. 

24. Dolan, M.E., Stine, L., Mitchell, R.B., Moschel, R.C., Pegg, A.E. Modulation of mammalian 

O 6 -alkylguanine-DNA alkyltransferase in vivo by O 6 -benzylguanine and its effect on the 

18

sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. 

Cancer Commun., 2:371-377, 1990. 

25. Dolan, M.E., Mitchell, R.B., Mummert, C., Moschel, R.C., Pegg, A.E. Effect of O 6 - 

benzylguanine analogs on sensitivity of human tumor cells to the cytotoxic effects of alkylating 

agents. Cancer Res., 51:3367-3372, 1991. 

26. Pegg, A.E, Wiest, L., Mummert, C., Dolan, M.E. Production of antibodies to peptide 

sequences present in human O 6 -alkylguanine-DNA alkyltransferase and their use to detect 

this protein in cell extracts. Carcinogenesis, 12:1671-1677, 1991. 

27. Pegg, A.E., Wiest, L., Mummert, C., Stine, L., Moschel R.C., Dolan, M.E. Use of antibodies 

to human O 6 -alkylguanine-DNA alkyltransferase to study the content of this protein in cells 

treated with O 6 -benzylguanine or N-methyl-N'-nitro-N-nitrosoguanidine. Carcinogenesis, 

12:1679-1683, 1991. 

28. Dolan, M.E. Pegg, A.E., Dumenco, L.L., Moschel, R.C., Gerson, S.L. Comparison of the 

inactivation of mammalian and bacterial O 6 -alkylguanine-DNA alkyltransferases by O 6 - 

benzylguanine and O 6 -methylguanine. Carcinogenesis, 12:2305-2309, 1991. 

29. Lukash, L.L., Boldt, J., Pegg, A.E., Dolan, M.E., Maher, V.M., McCormick, J.J. Effect of O 6 - 

alkylguanine-DNA alkyltransferase on the frequency and spectrum of mutations induced by Nmethyl-N'-nitro-N-nitrosoguanidine 

in the HPRT gene of diploid human fibroblasts. Mutation 

Res., 250:397-409, 1991. 

30. Mitchell, R.B., Moschel, R.C., and Dolan, M.E. Effect of O 6 -benzylguanine on the sensitivity of 

human tumor xenografts to 3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand 

cross-link formation. Cancer Res., 52:1171-1175, 1992. 

31. Moschel, R.C., McDougall, M.G., Dolan, M.E., Stine, L., Pegg, A.E. Structural features of 

substituted purine derivatives compatible with depletion of human O 6 -alkylguanine-DNA 

alkyltransferase. J. Med. Chem., 35:4486-4491, 1992. 

32. Friedman, H.S., Dolan, M.E., Moschel, R.C., Pegg, A.E., Felker, G.M., Rich, J., Bigner, D.D., 

Schold, S.C. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma 

multiforme. J. Natl. Cancer Inst., 84:1926-1931, 1992. 

33. Mitchell, R.B., Dolan, M.E. Effect of temozolomide and dacarbazine on O 6 -alkylguanine-DNA 

alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-Bis(2chloroethyl)-1-nitrosourea. 

Cancer Chemo. Pcol., 32:59-63, 1993. 

34. Jacoby, R.F., Bolt, M.J.G., Dolan, M.E., Otto, G., Dudeja, P., Sitrin, M.D., Brasitus, T.A. 

Supplemental dietary calcium fails to alter the acute effects of 1,2-dimethylhydrazine on 

O 6 methylguanine, O 6 -alkylguanine-DNA alkyltransferase and cellular proliferation in the rat 

colon. Carcinogenesis, 14:1175-1179, 1993. 

35. Dolan, M.E., Pegg, A.E., Biser, N.D., Moschel, R.C., English, H.F. Effect of O 6 - 

benzylguanine on response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327 G 

model of prostatic cancer. Cancer Chemo. Pcol., 32:221-225, 1993. 

19

36. Bishop, R.E., Dunn, L.L., Pauly, G.T., Dolan, M.E., Moschel, R.C. The role of O 6 - 

alkylguanine-DNA alkyltransferase in protecting rat 4 cells against the mutagenic effects of O 6 - 

substituted guanine residues incorporated in codon 12 of the H-ras gene. Carcinogenesis, 

14:593-598, 1993. 

37. Dolan, M.E., Pegg, A.E., Moschel, R.C., Grindey G.B. Effect of O 6 -benzylguanine on the 

sensitivity of human colon tumor xenografts of BCNU. Biochemical Pcology, 46:285-290, 

1993. 

38. Vokes, E.E., Dolan, M.E., Krishnasamy, S., Mick, R., Ratain, M.J., Berezin, F., Brachman, D., 

Whitman, G., Schilsky, R.L., Weichselbaum, R.R., Charette J., Dohrmann III, G.J., 

Hekmatpanah, J. 5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with 

concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis. 

Annals of Oncology, 4:591-595, 1993. 

39. Felker, G.M., Friedman, H.S., Dolan, M.E., Moschel, R.C., Schold, C. Treatment of 

subcutaneous and intracranial brain tumor xenografts with O 6 -benzylguanine and 1,3-bis(2chloroethyl)-1-nitrosourea. 

Cancer Chemo. Pcol., 32:471-476, 1993. 

40. Marathi, U.K., Kroes, R.A., Dolan, M.E., Erickson, L.C. Prolonged depletion of 

O 6 methylguanine DNA methyltransferase activity (MGMT) following exposure to O 6 - 

benzylguanine with or without streptozotocin enhances 1,3 bis(2-chloroethyl)-1 nitrosourea 

sensitivity in vitro. Cancer Res., 53:4281-4286, 1993. 

41. Sarkar, A., Dolan, M.E., Gonzalez, G.G., Marton, L.J., Pegg, A.E., Deen, D.F. The effects of 

O 6 -benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in 

nitrosourea-resistant SF-763 cells. Cancer Chemo. Pcol., 32:477-481, 1993. 

42. Pegg, A.E., Boosalis, M., Samson, L., Moschel, R.C., Byers, T.L., Dolan, M.E. Mechanism of 

inactivation of human O 6 -alkylguanine-DNA alkyltransferase by O 6 -benzylguanine. 

Biochemistry, 32:11998-12006, 1993. 

43. Chae, M-Y, McDougall, M.G., Dolan, M.E., Swenn, K., Pegg, A.E., Moschel, R.C. Substituted 

O 6 -benzylguanine derivatives and their inactivation of human O 6 -alkylguanine-DNA 

alkyltransferase. J. Med. Chem., 37:342-347, 1994. 

44. Friedman H.S., Dolan, M.E., Kaufmann S.H., Colvin O.M., Griffith O.W., Moschel R.C., Schold 

S.C., Bigner D.D., Ali-Osman F. Elevated DNA polymerase-α, DNA polymerase-β, and DNA 

topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant 

to nitrosoureas and topotecan. Cancer Res., 54:3487-3493, 1994. 

45. Marathi U.K., Dolan, M.E., Erickson, L.C. Extended depletion of O 6 -methylguanine DNA 

methyltransferase activity following O 6 -benzyl-2'-deoxyguanosine, or O 6 -benzylguanine 

combined with streptozotocin treatment enhances 1,3 bis (2-chloroethyl)-1-nitrosourea 

cytotoxicity. Cancer Res., 54:4371-4375, 1994. 

46. Dolan, M.E., Fleig, M.J., Feuerstein, B.G., Basu, H.S., Luk, G.D., Casero, R.A., Marton, L.J. 

Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane (BE-4-4-4-4) on human tumor 

xenografts. Cancer Res., 54:4698-4702, 1994. 

20

47. Dolan, M.E., Chae M-Y., Pegg, A.E., Mullen J.H., Friedman H.S., Moschel R.C. Metabolism 

of O 6 -benzylguanine, an inactivator of O 6 -alkylguanine-DNA alkyltransferase. Cancer Res., 

54:5123-5130, 1994. 

48. Mitchell, R.B., Dolan, M.E., Janisch, L., Vogelzang, N.J., Ratain, M.J., Schilsky, R.L. 

Sequential therapy with dacarbazine and carmustine: A phase I study. Cancer Chemo. Pcol., 

34:509-514, 1994. 

49. Dolan, M.E., Pegg, A.E., Moschel R.C., Vishnuvajjala B.R., Flora K.P., Grever M.R., Friedman 

H.S. Biodistribution of O 6 -benzylguanine and its effectiveness against human brain tumor 

xenografts when administered in polyethylene glycol or cremophor-El. Cancer Chemo. Pcol., 

35:121-126, 1994. 

50. Kokkinakis D.M., Moschel R.C., Pegg A.E., Dolan, M.E., Schold Jr. S.C. Metabolism and 

disposition of O 6 -benzy-2'-deoxyguanosine in Sprague Dawley rats. Chemical Res. 

Toxicology, 7:762-769, 1994. 

51. Marathi U.K., Dolan, M.E., Erickson L.C. Anti-neoplastic activity of sequenced administration 

of O 6 -benzylguanine, streptozotocin, and 1,3 bis(2-chloroethyl)-1-nitrosourea in vitro and in 

vivo. Biochem. Pcol., 48:2127-2134, 1994. 

52. Chae, M-Y., Swenn, K., Kanugula, S., Dolan, M.E., Pegg, A.E., Moschel, R.C. 8-substituted 

O 6 -benzylguanine, substituted 6(4)-benzyloxypyrimidine and related derivatives as inactivators 

of human O 6 -alkylguanine-DNA alkyltransferase. J. Med. Chem., 38:359-365, 1995. 

53. Friedman, H.S., Dolan, M.E., Pegg, A.E., Marcelli, S., Keir, S., Catino, J.J., Bigner, D.D., 

Schold, S.C. Activity of temozolomide in the treatment of central nervous system tumor 

xenografts. Cancer Res., 55:2853-2857, 1995. 

54. Pegg, A.E., Swenn, K., Chae, M-Y., Dolan, M.E., Moschel, R.C. Increased killing of prostate, 

breast, colon and lung tumor cells by the combination of inactivators of O 6 -alkylguanine-DNA 

alkyltransferase and N,N 1 -bis(2-chloroethyl)-N-nitrosourea. Biochem. Pcol., 50:1141-1148, 

1995. 

55. Gupta, E., Olopade, O.I., Ratain, M.J., Mick, R., Berezin, F.K., Benson, A.B., Dolan, M.E. 

Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. Clin. 

Cancer Res., 1:1133-1138, 1995. 

56. Roy, S.K., Korzekwa, K.R., Gonzalez, F.J., Moschel, R.C., Dolan, M.E. Human liver oxidative 

metabolism of O 6 -benzylguanine. Biochem. Pcol., 50:1385-1389, 1995. 

57. Roy, S.K., Gupta, E., Dolan, M.E. Pharmacokinetics of O 6 -benzylguanine in rats and its 

metabolism by rat liver microsomes. Drug Metab Disp., 23:1394-1399, 1995. 

58. Fleming, G.F., Vokes, E.E., Buse, J.B., Mick, R., Dushay, J., Levitan, D., Dolan, M.E. 

Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with 

and without diabetes mellitus. Cancer Chemother. Pcol., 37:569-573, 1996. 

59. Belanich, M., Randall, T., Pastor, M.A., Kibitel, J.T., Alas, L.G., Dolan, M.E., Schold, Jr., S.C., 

Gander, M., Lejeune, F.J., Li, B.F.L., White, A.B., Wasserman, P., Citron, M.L., Yarosh, D.B. 

21

Intracellular localization and intercellular heterogeneity of the human DNA repair protein O 6 - 

methylguanine-DNA methyltransferase. Cancer Chemother Pcol, 37:547-555, 1996. 

60. Vokes, E.E., Mick, R., Kies, M.S., Dolan, M.E., Malone, D., Athanasiadis, I., Haraf, D.J., 

Kozloff, M., Weichselbaum, R.R., Ratain, M.J. Pharmacodynamics of fluorouracil-based 

induction chemotherapy in advanced head and neck cancer. J Clin Oncol., 14:1663-1671, 

1996. 

61. Roy, S.K., Moschel, R.C., Dolan, M.E. Pharmacokinetics and metabolism in rats of 2,4diamino-6-benzyloxy-5-nitrosopyrimidine, 

an inactivator of O 6 -alkylguanine-DNA 

alkyltransferase. Drug Metab Disp., 24:1-7, 1996. 

62. Friedman, H.S., Johnson S.P., Dong, Q., Schold, S.C., Rasheed Ahmed, B.K., Bigner, S. H., 

Ali-Osman, F., Dolan, M.E., Colvin, O.M., Houghton, P., Germain, G., Drummond, J.T., Keir, 

S., Marcelli, S., Bigner, D.D., Modrich, P. Methylator resistance mediated by mismatch repair 

deficiency in a glioblastoma multiforme xenograft. Cancer Research, 57:2933-2936, 1997. 

63. Johnston, P.G., Mick, R., Recant, W., Behan, K.A., Dolan, M.E., Ratain, M.J., Beckman, E., 

Weichselbaum, R.R., Allegra, C.J., and Vokes, E.E. Thymidylate synthase expression and 

response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J 

Natl Cancer Inst., 89:308-313, 1997. 

64. Kurpad, S.N., Dolan, M.E., McLendon, R.E., Archer, G.E., Moschel, R.C., Pegg, A.E., Bigner, 

D.D., Friedman, H.S. Intraarterial O 6 -benzylguanine enables the specific therapy of 

nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2chloroethyl)-1-nitrosourea. 

Cancer Chemother Pcol., 39:307-316, 1997. 

65. Zagaja, G.P., Shrivastav, M., Fleig, M.J., Marton, L.J., Rinker-Schaeffer, C.W., Dolan, M.E. 

Effects of polyamine analogues on prostatic adenocarcinoma cells in vitro and in vivo. Cancer 

Chemotherapy Pcology., 41:505-512, 1998. 

66. Dolan, M.E., Roy, S.K., Helft, P., Garbiras, B.J., Paras, P., Chae, M.Y., Moschel, R.C., Pegg, 

A.E. O 6 -Alkylguanine-DNA alkyltranserase inactivation by ester prodrugs of O 6 -benzylguanine 

derivatives and their rate of hydrolysis by cellular esterases. Biochem Pcol., 55:1701- 

1709,1998. 

67. Dolan, M.E., Roy, S.K., Fasanmade, A.A., Paras, P.R., Schilsky, R.L., Ratain, M.J. O 6 - 

Benzylguanine in humans: Metabolic, pharmacokinetic and pharmacodynamic findings. J. 

Clin Oncol., 16:1803-1810, 1998. 

68. Dolan, M.E., Frydman, B., Thompson, C.B., Diamond, A.M., Garbiras, B.J., Safa, A.R., Beck, 

W.T., Marton, L.J. Effects of 1,2-naphthoquinones on human tumor cell growth and lack of 

cross-resistance with other anticancer agents. Anti-Cancer Drugs, 9:437-448, 1998. 

69. Friedman, H.S., Kokkinakis, D.M., Pluda, J., Friedman, A.H., Cokgor, I., Haglund, M.M., 

Ashley, D.M., Rich, J., Dolan, M.E., Pegg, A.E., Moschel, R.M., McLendon, R.E., Kerby, T., 

Herdon, J.E., Bigner, D.D., Schold Jr., S.C. Phase I trial of O 6 -benzylguanine for patients 

undergoing surgery for malignant glioma. J Clin Oncol., 16:3570-3575, 1998. 

70. Friedman, H.S., Pegg, A.E., Johnson, S.P., Loktionova, N.A., Dolan, M.E., Modrich, P., 

Moschel, R.C., Struck, R., Brent, T.P., Luderman, S., Bullock, N., Kilborn, C., Keir, S., Dong, 

22

Q., Bigner, D.D., Colvin, O.M. Modulation of cyclophosphamide activity of O 6 -alkylguanine- 

DNA alkyltransferase. Cancer Chemo Pcol., 43:80-85, 1999. 

71. Wu, M.H., Lohrbach, K.E., Olopade, O.I., Kokkinakis, D.M., Friedman, H.S., Dolan, M.E. Lack 

of evidence for a polymorphism at Codon 160 of human O 6 -alkylguanine-DNA 

alkyltransferase gene in normal tissue and cancer. Clin Cancer Res., 5:209-213, 1999. 

72. Humerickhouse, R.A., Dolan, M.E., Haraf, D.J., Brockstein, B.E., Stenson, K., Kies, M., 

Sulzen, L., Ratain, M.J., Vokes, E.E. Phase I study of eniluracil, a dihydropyrimidine 

dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with 

recurrent or advanced head and neck cancer. Clin Cancer Res., 5:291-298, 1999. 

73. Dolan, M.E., Ferries-Rowe, E., McRae, B.L., Belanich, M., van Seventer, G.A., Koeppen, H., 

Pezen, D., Kuzel, T.M., Yarosh, D.B. O 6 -Alkylguanine DNA alkyltransferase activity in 

mycosis fungoides: implications for treatment with alkylating agents. Clin Cancer Res., 

5:2059-2064, 1999. 

74. Long, L., McCabe, D.R., Dolan, M.E. Determination of 8-oxoguanine in human plasma and 

urine by high-performance liguid chromatography with electrochemical detection. J Chromat 

B., 731:241-249, 1999. 

75. Cai, Y., Wu, M.H., Ludeman, S., Grdina, D.J., Dolan, M.E. Role of O 6 -alkylguanine-DNA 

alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity. 

Cancer Res., 59:3059-3063, 1999. 

76. Wali, R.K., Skarosi, S., Hart, J., Zhang, Y., Dolan, M.E., Moschel, R.C., Nguyen, L., Mustafi, 

R., Brasitus, T.A., Bissonnette, M. Inhibition of O 6 -methylguanine-DNA methyltransferase 

increases azoxymethane-induced colonic tumors in rats. Carcinogenesis, 20:2355-2360, 

1999. 

77. Humerickhouse, R., Lohrback, L., Bosron, W.F., Dolan, M.E. Characterization of CPT-11 

hydrolosis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res., 

60:1189-1192, 2000. 

78. Chmura, S.J., Dolan, M.E., Cha, A., Mauceri, H.J., Kufe, D.W., Weichselbaum, R.R. The PKC 

inhibitor chelerythrine chloride induces apoptosis and demonstrates potent anti-tumor activity 

in vivo. Clin Cancer Res., 6:737-742, 2000. 

79. Vokes, E.E., Kies, M.S., Haraf, D.J., Stenson, K., List, M., Humerickhouse, R., Dolan, M.E., 

Pelzer, H., Sulzen, L., Witt, M.E., Hsieh, C., Mittal, B.B., Weichselbaum, R.R. Concomitant 

chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J 

Clin Oncol., 18:1652-1661, 2000. 

80. Ewesuedo, R.B., Dolan, M.E. Pharmacokinetics of oral O 6 -benzylguanine and evidence of 

interaction with oral ketoconazole in Rat. Cancer Chemo Pcol., 46:150-155, 2000. 

81. Schilsky, R.S., Dolan, M.E., Bertucci, D., Ewesuedo, R.B., Vogelzang, N.J., Mani, S., Wilson, 

L.R., and Ratain, M.J. Phase I clinical and pharmacological study of O 6 -benzylguanine 

followed by carmustine in patients with advanced cancer. Clin Cancer Res., 6:3025-3031, 

2000. 

23

82. Friedman, H.S., Pluda, J., Ewesuedo, R.B., Long, L., Friedman, A.H., Cokgor, I., Colvin, O.M., 

Haglund, M.M., Ashley, D.M., Rich, J.N., Quinn, J.A., Sampson, J., Pegg, A.E., Moschel, R.C., 

McLendon, R.E., Stewart, E.S., Tourt-Uhlig, S., Garcia-Turner, A.M., Herndon II, J.E., Bigner, 

D.D., Dolan, M.E. Phase I trial of BCNU plus O 6 -benzylguanine for patients with recurrent or 

progressive malignant glioma. J Clin Oncol., 18:3522-3528, 2000. 

83. Long, L., Berg, S.L., Roy, S.K., McCully, C.L., Song-Yoo, H. W., Moschel, R.C., Balis, F.M., 

Dolan, M.E. Plasma and cerebrospinal fluid pharmacokinetics of O 6 -benzylguanine and 

analogs in non-human primates. Clin Cancer Res., 6:3662-3669, 2000. 

84. Cai, Y., Wu, M.H., Xu-Welliver, M., Pegg, A.E., Ludeman, S.M., Dolan, M.E. Effect of O 6 - 

benzylguanine on alkylating agent-induced toxicity and mutagenicity in CHO cells expressing 

wild type and mutant O 6 -alkylguanine-DNA alkyltransferases. Cancer Res., 60:5464-5469, 

2000. 

85. Patel, V.J, Elion, G.B., Houghton, P.J., Keir, S., Pegg, A.E., Dolan, M.E., Bigner, D.D., 

Friedman, H.S. Schedule dependent activity of temozolomide plus CPT-11 against a human 

central nervous system tumor-derived xenograft. Clin Cancer Res., 6:4154-4157, 2000. 

86. Long, L., Moschel, R.C., Dolan, M. E. Debenzylation of O 6 -benzyl-8-oxoguanine in human 

liver: Implications for O 6 -benzylguanine metabolism. Biochem Pcol., 61:721-726, 2000. 

87. Keir, S.T., Dolan, M.E., Pegg, A.E., Lawless, A., Moschel, R.C., Bigner, D.D., Friedman, H.S. 

O 6 -Benzylguanine-mediated enhancement of nitrosoureas activity in Mer-central nervous 

system tumor xenografts—implications for clinical trials. Cancer Chemother Pcol., 45:437- 

440, 2000. 

88. Benson A.B., Olopade O.I, Ratain M.J, Rademaker A., Mobarhan S., Stucky-Marshall L., 

French S., Dolan, M.E. Chronic daily low dose of 4-methyl-5 (2-pyrazinyl)-1,2 dithiole-3-thione 

(oltipraz) in patients with previously resected colon polyps and first degree female relatives of 

breast cancer patients. Clin Cancer Res., 6:3870-3877, 2000. 

89. Rhines, L.D., Sampath, P., Dolan, M.E., Tyler, B.M., Brem, H., Weingart, J. O 6 - 

Benzylguanine potentiates the antitumor effect of locally delivered carmustine against an 

intracranial rat glioma. Cancer Res., 60:6307-6310, 2000. 

90. Ewesuedo, R.B., Wilson, L.R., Friedman, H.S., Moschel, R.C., and Dolan, M.E. Inactivation 

of O 6 -alkylguanine-DNA alkyltransferase by 8-substituted O 6 -benzylguanine analogs in mice. 

Cancer Chemo Pcol., 47:63-69, 2001. 

91. Wu, M.H., Liebowitz, D.N., Smith, S.L., Williams, S.F., and Dolan, M.E. Efficient expression of 

foreign genes in human CD34+ hematopoietic precursor cells using electroporation. Gene 

Therapy, 8:384-390, 2001. 

92. Wu, M.H., Smith, S.L., Danet, G.H., Lin, A.M., Williams, S.F., Liebowitz, D.N. and Dolan. M.E. 

Optimization of culture conditions to enhance transfection of human CD34 + cell by 

electroporation. Bone Marrow Transplant, 27:1201-1209, 2001. 

93. Hu, Y.J., Korotkov, K.V., Mehta, R., Hatfield, D.L., Rotimi, C.N., Luke, A., Prewitt, T.E., 

Cooper, R.S., Stock, W., Vokes, E.E., Dolan, M.E., Gladyshev, V.N., and Diamond, A.M. 

24

Distribution and functional consequences of nucleotide polymorphisms in the 3‘-untranslated 

region of the human Sep 15 gene. Cancer Res., 61:2307-2310, 2001. 

94. Cai, Y., Ludeman, S.M., Wilson, L.R., Chung, A.B., and Dolan, M.E. Effect of O 6 - 

benzylguanine on nitrogen mustard-induced toxicity, apoptosis and mutagenicity in CHO cells. 

Molec Cancer Ther., 1:21-28, 2001. 

95. Wu, M.H., Smith, S.L., and Dolan, M.E. High efficiency electroporation of human umbilical 

cord blood CD34+ hematopoietic precursor cells. Stem Cells, 19:492-499, 2001. 

96. Long, L., and Dolan, M.E. Role of CYP450 isoenzymes in metabolism of O 6 -benzylguanine: 

Implications for dacarbazine activation. Clinical Cancer Res., 7:4239-4244, 2001. 

97. Balu, N., Gamcsik, M.P., Colvin, M.E., Colvin, O.M., Dolan, M.E., and Ludeman, S.M. 

Modified guanines representing O 6 -alkylation by the cyclophosphamide metabolites acrolein 

and chloroacetaldehyde: Synthesis, stability, and ab initio studies. Chem Res Toxicol., 

15:380-387, 2002. 

98. Park, D.K., Ryan, C.W., Dolan, M.E., Vogelzang, N.J., and Stadler, W.M. A Phase II trial of 

oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemother Pcol., 

50:160-162, 2002. 

99. Wu, M.H, Yan, B., Hummerickhouse, R. and Dolan, M.E. Irinotecan activation by human 

carboxylesterase hCE-1 and hCE-2 in colorectal adenocarcinoma cells. Clinical Cancer 

Research, 8:2696-2700, 2002. 

100. Dolan, M.E., Posner, M., Karrison, T., Radosta, J., Steinberg, G., Bertucci, D., Vujasin, L., 

Ratain, M.J. Determination of the optimal modulatory dose of O 6 -benzylguanine in patients 

with surgically respectable tumors. Clinical Cancer Research, 5:2519-2523, 2002. 

101. Friedman, H.S., Keir, S., Pegg, A.E., Houghton, P.J., Colvin, O.M., Moschel, R.C., Bigner, 

D.D., and Dolan, M.E. O 6 -Benzylguanine-Mediated enhancement of combination 

chemotherapy. Molec Cancer Ther., 1:943-948, 2002. 

102. Quinn, J.A., Pluda, J., Dolan, M.E., Delaney, S., Kaplan, R., Rich, J.N., Friedman, A.H., 

Reardon, D.A., Sampson, J.H., Colvin, O.M., Haglund, M.M., Pegg, A.E., Moschel, R.C., 

McLendon, R.E., Provenzale, J.M., Gururangan, S., Tourt-Uhlig, S., Herndon, J.E., 2nd, 

Bigner, D.D., Friedman, H.S. Phase II trial of carmustine plus O 6 -benzylguanine for patients 

with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol., 20:2277- 

2283, 2002. 

103. Smith, S.M., Ludeman, S.M., Wilson, L.R., Springer, J.B., Gandhi, M.C., and Dolan, M.E. 

Selective enhancement of Ifosfamide-induced toxicity in Chinese hamster ovary cells. Cancer 

Chemother Pcol., 52:291-302, 2003. 

104. Fishel, M.L., Delaney, S.M., Friesen, L.D., Hansen, R.J., Zuhowski, E.G., Moschel, R.C., 

Egorin, M.J., and Dolan, M.E. Enhancement of platinum-induced cytotoxicity by O 6 - 

benzylguanine. Molec Cancer Ther., 2:633-640, 2003. 

25

105. Wu, M.H., Chen, P., Remo, B.F., Cook, Jr., E.H., Das, S., and Dolan, M.E. Characterization 

of multiple promoters in the human carboxylesterase 2 gene. Pharmacogenetics, 13:425-435, 

2003. 

106. Yeager, N.D., Dolan, M.E., Gastier, J.M., Gross, T.G., Delaney, S., Frick, J., Ruymann, F.B., 

and Ewesuedo, R. O 6 -methylguanine-DNA methyltransferase activity and promoter 

methylation status in pediatric rhabdomyosarcoma. J Pediatr Hematol Oncol., 25:941-947, 

2003. 

107. Dolan, M.E., Newbold, K.G., Nagasubramanian, R., Wu, X., Ratain, M.J., Cook, Jr., E.H., and 

Badner, J.A. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. 

Cancer Res, 64(12):4353-4346, 2004. 

108. Springer, J.B., Chang, Y.H., Koo, K.I., Colvin, O.M., Colvin, M.E., Flowers, J.L., Delaney S.M., 

Dolan, M.E., and Ludeman, S.M. I,3- versus 1,5-Intramolecular alkylation reactions in 

isophosphoramide and phosphoramide mustards. Chem Res Toxicol., 17(9):1217-1226, 

2004. 

109. Wu, M.H., Chen, P., Wu, X., Liu, W., Strom, S., Das, S., Cook, Jr., E.H., and Dolan, M.E. 

Determination and analysis of single nucleotide polymorphisms and haplotype structure of the 

human carboxylesterase 2 gene. Pharmacogenetics, 14(9):595-605, 2004. 

110. Hu, Y.J., Dolan, M.E., Bae, R., Yee, H., Roy, M., Glickman, R., Kiremidjian-Schumacher, L., 

Diamond, A.M. Allelic loss of the GPx-1 locus in cancer of the head and neck. Biol Trace 

Elem Res., 101(2):97-106, 2004. PMID 15557674 

111. Bacolod, M.D., Johnson, S.P., Pegg, A.E., Dolan, M.E., Moschel, R.C., Bullock, N.S., Fang, 

Q., Colvin, O.M., Modrich, P., Bigner, D.D., Friedman, H.S. Brain tumor cell lines resistant to 

O 6 -benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O 6 -alkylguanine- 

DNA alkyltransferase mutations. Mol Cancer Ther., 3(9):1127-35, 2004. PMID 15367707 

112. Fishel M.L., Newell D.R., Griffin R.J., Davison R., Wang L.Z., Curtin N.J., Zuhowski E.G., 

Kasza K., Egorin M.J., Moschel R.C., Dolan M.E. Effect of cell inhibition on cisplatin-induced 

cytotoxicity. J Pharmacol Exp Ther., 312:206-213, 2005. PMID15304523 

113. Fishel, M.L., Gamcsik, M.P., Zuhowski, E.G., Maher, V.M., Karrison, T., Moschel, R.C., 

Egorin, M.J., and Dolan, M.E. Role of glutathione and nucleotide excision repair NER in 

modulation of cisplatin activity of O 6 -benzylguanine. Cancer Chemother Pharmacol., 555:333- 

42, 2005. PMID 15723259 

114. Liu W., Innocenti F., Wu M.H., Desai A., Dolan M.E., Cook E.H., Ratain, M.J. A functional 

common polymorphism in an Sp1 recognition site of the epidermal growth factor receptor 

gene promoter. Cancer Res., 65:46-53, 2005. PMID15665278 

115. Hansen, R.J., Nagasubramanian, R, Delaney S.M., Cherian, M.M., Kogan, S.C., Lin, S., 

Dolan, M.E. Role of O 6 -alkylguanine-DNA alkyltransferase in protecting against BCNUinduced 

long-term toxicities. J. Pharmacol Exp Ther., 315:1247-1255, 2005. PMID16126841 

116. Pasche, B., Knobloch, T.J., Bian, Y., Liu, J., Phukan, S., Kaklamani, V., Baddi, L., Rosman, 

D., Frankel, W., Prior, T.W., Schuller, D.E., Dolan, M.E., Vokes, E.E., Lane, W.S., Huang, C- 

C., Caldes, T., Di Cristofano, A., Hampel, H., Nilsson IM., vonHeijne, G., Fodde, R., Murty, 

26

V.V.V.S., de al Chapelle, A., Weghorst, C.M. TGFBR1*6A is somatically acquired at high 

frequency in cancer and switches TGF- growth inhibitory signals into growth stimulatory 

signals. JAMA, 294:1634-1646, 2005. PMID16204663 

117. Quinn, J.A., Desjardins, A., Weingart, J., Brem, H., Dolan, M.E., Delaney, S.M., 

Vrendenburgh, J. Rich, J. Friedman, A.H., Reardon, D.A., Sampson, J.H., Pegg, A.E., 

Moschel, R.C., Birch R., McLendon, R.E., Provenzale, J.M., Gururangan, S., Dancey, J.E., 

Maxwell, J., Tourt-Uhlig, S., Herndon, J.E., Bigner, D.D. Friedman, H.S., Phase I trial of 

temozolomide plus O 6 -benzylguanine for patients with recurrent or progressive malignant 

glioma. J Clin Oncol., 1;23(28):7178-87, 2005. PMID 16192602 

118. Cheng, C.L., Johnson, S.P., Keir, S.T., Quinn, J.A., Ali-Osman, F, Szabo, C., Hongshan, Li, 

Salzman, A.L., Dolan, M.E., Modrich, P., Bigner, D.D., Friedman, H.S. Poly(ADP- ribose) 

polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deificient 

malignant glioma xenograft. Mol Cancer Ther., 4(9): 1364-1368, 2005. PMID16170028 

119. Gajewski, T.F., Sosman, J., Gerson, S.L., Liu, L., Dolan, M.E., Lin, S., Vokes, E.E. Phase II 

trial of the O 6 -alkylguanine DNA alkyltransferase inhibitor O 6 -benzylguanine and 1,3-bis(2chloroethyl)-1-nitrosourea 

in advanced melanoma. Clin Cancer Res., 11(21):7861-5, 2005. 

PMID16278409 

120. Fishel M.L., Rabik C.A., Bleibel K., Li X., Moschel R.C. and Dolan M.E. Role of GADD34 in 

modulation of cisplatin cytotoxicity. Biochem Pharm., 71:239-247, 2005. PMID16325149 

121. Ryan, C.W., Dolan M.E., Brockstein, B.B., McLendon, R., Delaney, S.M., Samuels, B.L., 

Agamah, E.S. and Vokes, E.E. A Phase II Trial Of O 6 -Benzylguanine and Carmustine In 

Patients With Advanced Soft Tissue Sarcoma. Cancer Chemother Pharmacol., 58(5); 634-9, 

2006. PMID16520986 

122. Weingart, J., Grossman, S.A., Carson, K.A., Fisher, J.D. Delaney, S.M. Rosenbum, M.L. Olivi, 

A., Judy, K. Tatter, S.B., Dolan, M.E. Phase I Trial of Polifeprosan 20 with Carmustine 

Implant Plus Continuous Infusion of Intravenous O 6 -Benzylguanine in Adults with Recurrent 

Malignant Glioma: A New Approaches to Brain Tumor Therapy CNS Consortium Trial, JCO, 

25(4); 399-404, 2007. PMID17264335 PMCID: PMC2556256 

123. Zhang, W., Bleibel, W.K., Roe, C.R., Cox, N.J., Dolan, M.E. Gender-specific Differences in 

Expression in Lymphoblastoid Cell Lines. Pharmacogenetics and Genomics, 17: 447-450, 

2007. PMID17502836 PMCID: PMC2716706 

124. Huang, R.S., Kistner, E.O., Bleibel, W.K., Shukla, S.J., Dolan, M.E. Effect of population and 

Gender on Chemotherapeutic Agent-Induced Cytotoxicity. Molecular Cancer Therapeutics, 

6(1); 31-36, 2007. PMID17237264 PMCID: PMC2669540 

125. Hansen, R.J., Nagasubramanian, R., Delaney, S.M., Samson, L.D., and Dolan, M.E., Role of 

O 6 -methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity 

and mutations in mice. Carcinogenesis, 28: 1111-1116, 2007. PMID17116724 

126. Huang, R. S., Duan, S., Bleibel, W. K. Kistner, E. O., Zhang, W., Clark, T. A., Chen, T.X., 

Schweitzer, A.C., Blume, J. E., Cox, N. J. and Dolan, M. E. A genome-wide approach to 

identify genetic variants that contribute to etoposide-induced cytotoxicity, PNAS, 104: 9758- 

9763, 2007. PMID17537913 PMCID: PMC1887589 

27

127. Hansen R.J., Ludeman S.M., Pegg A.E., Dolan, M.E. Role of MGMT in Protecting against 

Cyclophosphamide-induced toxicity in cells and animals. DNA Repair, 6: 1145-1155, 2007. 

PMID17485251 PMCID: PMC1989758 

128. Hartford, C.; Yang, W.; Cheng, C.; Fan, Y.; Trevino, L.; Pounds, S.; Neale, G.; Raimond, S.C.; 

Bogni, A.; Dolan, M.E.; Pui, C-H.; Relling, M.V. Genome scan implicates adhesion biological 

pathways in secondary leukemia. Leukemia, 21(10):2128-36. 2007. PMID17673902 

129. Huang, R.S., Duan, S., Shukla, S.J., Kistner, E.O., Clark, T.A., Chen, T.X., Schweitzer, A.C., 

Blume, J.E., Dolan, M.E. Identification of genetic variants contributing to Cisplatin-induced 

cytotoxicity using a genome-wide approach. Amer. J. Human Gen., 81(3):427-37. 2007 

PMID17701890 PMCID: PMC1950832 

130. Duan, S., Bleibel, W.K., Huang, S.R., Shukla, S.J., Wu, X., Badner, J.A., Dolan, M.E. Mapping 

genes that contribute to Daunorubicin-induced cytotoxicity. Cancer Res., 67(11):5425-5433, 

2007. PMID17545624 

131. Yamini, B.; Yu, X.; Dolan, M.E.; Wu, M.; Tang, F.; Veerapong, J.; Kufe, D.W.; Weichselbaum, 

R.R.; Temozolomide inhibits NF-kB Transcriptional Activity in Human Glioma Cells. Cancer 

Research, 67, 6889-6898, 2007. PMID17638900 

132. Horton T.M., Thompson P.A., Berg S.L., Adamson P.M., Ingle AM, Dolan M.E., Delaney SM, 

Hedge M., Weiss HL, Wu MF, Blaney SM. A Phase 1, PK and PD Study of A Phase 1, 

Pharmacokinetic and Pharmacodynamic Study of Temozolomide in Pediatric Patients with 

Refractory/Recurrent Leukemia: A Children's Oncology Group Study. J. Clin Oncol, 25:4922-8, 

2007. PMID: 17971589 

133. Zhang, W., Duan, S., Kistner, E. O., Bleibel, W. K., Huang, R. S., Clark, T. A., Chen, T. X., 

Schweitzer, A.C., Blume, J. E., Cox, N. J. and Dolan, M. E. Evaluation of Genetic Variation 

Contributing to Differences in Gene Expression Between Populations. Amer. J. Human 

Genetics, 82: 631-640, 2008. PMID18313023 PMCID: PMC2427223 

134. Shukla, S.J., Duan, S., Badner, J.A., Wu, X., and Dolan, M.E. Susceptibility Loci Involved in 

Cisplatin-Induced Cytotoxicity and Apoptosis. Pharmacogenetics and Genomics, 18: 253-262, 

2008. PMID 18300947 PMCID: PMC2567113 

135. Huang, R. S., Duan, S., Kistner, E. O., Bleibel, W. K. Delaney, S.M. Fackenthal, D. L., Das, S. 

and Dolan, M. E. Genetic Variants Contributing to Daunorubicin-Induced Cytotoxicity, Cancer 

Research, 68:3161-3168, 2008. PMID18451141 PMCID: PMC1950832 

136. Duan, S., Huang, R.S., Zhang, W., Bleibel, W.K., Roe, C.A., Clark, T.A., Chen, T.X., 

Schweitzer, A.C., Blume, J.E., Cox, N.J., and Dolan, M.E. Genetic Architecture of Transcript- 

Level Variation in Humans, Amer. J. Human Genetics, 82:1101-1113, 2008. PMID18439551 

PMCID: PMC2651622 

137. Huang, R.S., Duan, S., Kistner, E.O., Zhang, W., Bleibel, W.K., Cox, N. J. and Dolan, M.E. 

Identification of Genetic Variants and Gene Expression Relationships Associated with 

Pharmacogenes in Human. Pharmacogenetics and Genomics, 18:545-549, 2008. 

PMID18496134 PMCID: PMC2567052 

28

138. Odenike, O.M., Larson, R.A., Gajria, D., Dolan, M.E., Delaney, S.M., Karrison, T.G., Ratain, 

M.J., Stock, W. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2carboxaldehyde-thiosemicarbazone 

(3-AP) in combination with high dose cytarabine in 

patients with advanced myeloid leukemia. Invest New Drugs, 26(3): 233-239, 2008. 

PMID18217206 

139. Huang, R.S., Duan. S, Kistner, E.O., Hartford, C.M., Dolan, M.E. Genetic variants associated 

with carboplatin-induced cytotoxicity in cell lines derived from Africans, Molec Cancer Ther., 

7(9): 3038-3046, 2008. PMID18765826 

140. Yang, J., Bogni, A., Cheng, C., Bleibel, W.K., Cai, X., Fan, Y., Yang, W., Rocha, J.C.C., Pei, 

D., Liu, W., Dolan, M.E, Pui, C.H., and Relling, M.V. Etoposide Sensitivity Does Not Predict 

MLL Rearrangements or Risk of Therapy-related Acute Myeloid Leukemia. Clinical Pharmac 

Ther., 84: 691-697, 2008. PMID18509329 PMCID: PMC2583166 

141. Nagasubramanian, R., Hansen, R.J., Delaney, S.M., Cherian, M.M., Samson, L.D., Kogan, 

S.C., and Dolan, M.E. Survival and tumorigenesis in O 6 -methylguanine DNA 

methyltransferase deficient mice following cyclophosphamide exposure. Mutagenesis, 23(5), 

341-346, 2008 PMID18477655 PMCID: PMC2527341 

142. Rabik, C.A., Fishel, M.L., Holleran, J.L., Kasza, K., Kelley, M.R., Egorin, M.J., and M. Dolan, 

E. Enhancement of cisplatin cytotoxicity by O 6 -benzylguanine involves endoplasmic reticulum 

stress. JPET, 327: 442-452, 2008. PMID18664592 

143. Hartford CM, Duan S, Delaney SM, Mi S, Kistner EO, Lamba JK, Huang RS, Dolan ME. 

Population specific genetic variants important in susceptibility to cytarabine arabinoside 

cytotoxicity. Blood 10:2145-2153, 2009. PMID19109566 PMCID: PMC2652364 

144. Bleibel WK, Duan S, Huang RS, Kistner EO, Shukla SJ, Wu X, Badner JA, Dolan ME. 

Identification of genomic regions contributing to etoposide-induced cytotoxicity. Hum Genet. 

125:173-80, 2009 PMID19089452 PMCID: PMC2714550 

145. Zhang, W., Duan, S., Bleibel, W.K., Wisel, S.A., Huang, R.S., Wu, X., He, L., Clark, T.A., 

Chen, T.X., Schweitzer, A.C., Blume, J.E., Dolan, M.E., Cox, N.J. Identification of Common 

Genetic Variants that Account for Transcript Isoform Variation between Populations, Hum 

Genet., 125, 81-93, 2009. PMID19052777 PMCID: PMC2665168 

146. Shukla, S.J., Duan, S., Wu, X., Badner, J.A., Kasza, K., and Dolan, M.E. Whole Genome 

Approach Implicates CD44 in Cellular Resistance to Carboplatin, Human Genomics, 3, 128- 

142, 2009. PMID19164090 PMCID: PMC19164090 

147. Innocenti, F., Mirkov, S., Nagasubramanian, R., Ramírez, J., Liu, W., Bleibel, W.K., Shukla, 

S.J., Hennessy, K., Rosner, G.L., Cook, E. Jr., Dolan, M.E., and Ratain, M.J. The Werner‘s 

syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of 

topoisomerase inhibitors and platinum compounds, Cancer Chemo Pcol 63:881-887, 2009. 

PMID18677484 

148. Duan S, Zhang W, Bleibel WK, Cox NJ, and Dolan ME. SNPinProbe_1.0: A database for 

filtering out probes in the Affymetrix GeneChip(R) Human Exon 1.0 ST array potentially 

affected by SNPs. Bioinformation 2(10):469-70, 2008. PMID18841244 PMCID: PMC2561168 

29

149. Huang, R.S., Chen, P., Wisel, S., Duan, S., Zhang, W., Cook, E.H., Das, S., Cox, N.J., and 

Dolan, M.E. Population Specific GSTM1 Copy Number Variation. Human Mol Genet, 18: 366- 

372, 2009. PMID18948376 

150. Duan, S., Cox, N., and Dolan, M.E. FstSNP-HapMap3: a database of SNPs with High 

Population Differentiation for HapMap3. Bioinformation, 3(3):139-41, 2009. PMID19238253 


151. Zhang, W, Huang, S., and Dolan, M.E. Gene Set Enrichment Analyses Revealed Differences 

in Gene Expression Patterns between Males and Females. In Silico Biology, 9:6, 2009. PMID: 

19795565 PMCID: PMC2757739 

152. Zuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, Luo W, McCurrach ME, Yang MM, 

Dolan ME, Kogan SC, Downing JR, and Lowe SW. Mouse models of human AML accurately 

predict chemotherapy response. Genes Dev., 23(7):877-89, 2009. PMID19339691 


153. Harrison L, Ottley CJ, Pearson GD, Roche C, Wedge SR, Dolan ME, Newell DR, Tilby MJ. 

The kinase inhibitor O 6 -cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of 

cisplatin by mechanisms that are independent of its effect upon CDK2. Biochemical 

Pharmacology, 77:1586–15, 2009. PMID: 19426695 

154. Duan, S., Huang, R.S., Zhang, W., Bleibel, W.K., Kistner, E. O., Cox, N. J. and Dolan, M. E. 

Expression and Alternative Splicing of Folate Pathway Genes in HapMap Lymphoblastoid Cell 

Lines. Pharmacogenomics, 10: 549-63, 2009. PMID: 19374514 PMCID: PMC2709842 

155. Rabik, C.A., Maryon, E.B., Kasza, K., Shafer, J.T., Bartnik, C.M., and Dolan, M.E. Role of 

Copper Transporters in Resistance to Platinating Agents, Cancer Chemother Pharmacol., 

64:133–142, 2009. PMID18998134 PMCID: PMC2733887 

155. Innocent, F., Kroetz, D.L., Schuetz, E., Dolan, M.E., Ramirez, J., Relling, M., Chen, P., Das, 

S., Rosner, G.L., Ratain, M.J. Comprehensive Pharmacogenetic Analysis of Irinotecan 

Neutropenia and Pharmacokinetics. J. Clin. Oncol., 27:2604-2614, 2009. PMID: 19349540 

156. Duan S., Mi S, Zhang W., Dolan M.E. Comprehensive analysis of the impact of SNPs and 

CNVs on human microRNAs and their regulatory genes. RNA Biology, 6 (4), 2009. PMID: 

19458495 PMCID: PMC2826392 

157. Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, Bertuch AA, Blaney SM, 

Delaney SL, Hegde M, Berg S. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates 

the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status 

and O 6 -methylguanine-DNA methyltransferase activity. Mol Cancer Ther., 8:2232-42, 2009. 

PMID: 19671751 

158. Gamazon E., Zhang W., Huang S., Dolan, M.E., Cox N. A Pharmacogene Database 

Enhanced by the 1000 Genomes Project. Pharmacogenetics and Genomics, 19(10):829-32, 

2009. PMID: 19745786 NIHMS202805 

159. Stark A., Duan S., Zhang W., Huang S., Dolan M.E. Heritable and Non-genetic Factors as 

Variables of Cellular Phenotypes in Lymphoblastoid Cell Lines. Pharmacogenomic Journal, 

10(6):505-12, 2010. PMID: 20142840 NIHMSID: 221056 

30

160. Gamazon E., Zhang W., Dolan M.E., Cox N. Comprehensive Survey of SNPs in the Probes of 

the Affymetrix Exon Array using the 1000 Genomes Dataset. PLoS One, 5(2):e9366, 2010. 

PMID: 20186275 

161. Gamazon E.R., Zhang W., Konkashbaev A., Duan S., Kistner E.O., Nicolae D.L., Dolan M.E., 

Cox N.J. SCAN: SNP and Copy number Annotation. Bioinformatics, 26(2): 259-62, 2010. 

PMID: 19933162 PMCID: PMC2852202 

162. Nicolae D.L., Gamazon E., Zhang W., Duan S., Dolan M.E., Cox N.J. Trait Associated SNPs 

Are More Likely to be eQTLs: Annotation to Enhance Discovery from GWAS, PLoS Genet. 

6(4):e1000888, 2010. PMID 20369019 PMCID: PMC 2848547 

163. Gamazon E.R, Duan S, Zhang W. Huang R.S., Kistner E.O., Dolan M.E., Cox N.J. PACdb: A 

Database for Cell-based Pharmacogenomics. Pharmacogenetics and Genomics, 20 (4): 269- 

273, 2010. PMID: 20216476 NIHMSID: 221129 

164. Huang R.S., Johnatty S.E., Gamazon E., Ziliak D., Duan S., Zhang W., Kistner E.O., Chen P., 

Beesley J., Australian Ovarian Cancer Study Group, Mi S., O‘Donnell P.H., Fraiman Y.S., Das 

S., Cox N.J., deFazio A., Chenevix-Trench G., Dolan M.E. Germline Polymorphism 

Discovered via a Cell-based Genome-wide Approach Predicts Platinum Response in Ovarian 

Cancer. under review, 2010. 

165. O'Donnell P., Zhang W., Huang S., Gamazon E., Stark A., Dolan M.E. Population Differences 

in Platinum Toxicity as a Means to Identify Novel Genetic Susceptibility Variants. 

Pharmacogenetics and Genomics, 20(5):327-337, 2010. NIHMSID 221082 

166. Gamazon E.R., Huang R.S., Cox N.J., Dolan, M.E. Chemotherapeutic Drug Susceptibility 

Associated SNPs are Enriched in Expression Quantitative Trait Loci, PNAS, 107, 9287-9292, 

2010. PMID: 20442332 PMCID: PMC2889115 

167. Gamazon E.R., Im, H.K., Duan S., Lussier Y.A., Cox N.J., Dolan, M.E. and Zhang W. 

Exprtarget: an integrative approach to predicting human microRNA targets. PLoS One 

5(10):e13534, 2010. PMID: 20975837 

168. Stark, A.L., Zhang, W, O‘Donnell, P.H., Beiswanger, C.M., Huang, R.S., Cox. N.J., and Dolan, 

M.E. Population Differences in Rate of Proliferation of International HapMap Cell Lines, Amer. 

J. Human Genetics 87(6):829-33, 2010. PMID: 21109222 

169. Gamazon, E.R., Im, H.K., O‘Donnell, P.H., Ziliak, D, Stark, A.L., Cox, N.J., Dolan, M.E. and 

Huang, R.S., Comprehensive Evaluation of the Contribution of X Chromosome Genes to 

Platinum Sensitivity, Molec Cancer Ther., under review. 

E-Publications/Pathways 

1. Cyclophosphamide pathway: http://www.pharmgkb.org/search/pathway/pathway.jsp 

2. Ifosamide pathway: http://www.pharmgkb.org/search/pathway/pathway.jsp 

3. Platinating agent pathway: http://www.pharmgkb.org/search/pathway/pathway.jsp 

4. Etoposide Pharmacogenet Genomics, 19:552-3, 2009 

31

Invited Editorials/Commentaries 

1. Dolan, M.E. and Shilsky, R.L. Silence is golden: gene hypermethylation and survival in large 

cell lymphoma, JNCI, 94:6-7, 2002. PMID11773269 

2. Zhang, W. and Dolan, M.E. Ancestry-related Differences in Gene Expression: Findings may 

Enhance Understanding in Health Disparities between Populations, Pharmacogenomics, 

9:489-492, 2008. PMID18466094 PMCID: PMC2665165 

3. Zhang W., and Dolan M.E. Impact of the 1000 Genomes Project on the Next Wave of 

Pharmacogenomic Discovery, Pharmacogenomics, 1(2):249-56, 2010. PMID: 20136363 


4. Huang, R.S and Dolan, M.E. Approaches to Discovery of Pharmacogenomic Markers in 

Oncology: 2000-2010-2020, Pharmacogenomics, 11:471-474, 2010 (NIHMS198082) PMID: 

20350124 

5. Travis, L.B., Beard, C., Allan, J.M., Dahl, A.A., Feldman, D.R., Oldenburg, J., Daugaard, G., 

Kelly, J.L., Dolan, M.E., Hannigan, R., Constine, L.S., Oeffinger, K.C., Okunieff, P., 

Armstrong, G., Wiljer, D.., Miller, R.C., Gietema, J.A., vanLeeuwen, F.E., Williams, J.P., 

Nichols, C.R., Einhorn, L.H., Fossa, S.D. Testicular Cancer Survivorship: Research Strategies 

and Recommendations, JNCI, 102(15):1114-30, 2010 PMID: 20585105 

Reviews 

1. Dolan, M.E. Quantitative dose-response function for chloroethylnitrosoureas in cell culture. 

TCA Reports, 17:6, 1983. 

2. Pegg, A.E. and Dolan, M.E. Properties and assay of mammalian O 6 -alkylguanine DNAalkyltransferase. 

Clin Pharmac. Ther., 34:167-179, 1987. 

3. Pegg, A.E., Dolan, M.E., and Moschel, R.C. Structure function and inhibition of O 6 - 

alkylguanine-DNA alkyltransferase. Progress Nucleic Acid Res. Mol. Biol., 51:167-223, 1995. 

4. Dolan, M.E. and Pegg, A.E. O 6 -Benzylguanine and its role in chemotherapy. Clin Cancer 

Res., 3:837-847, 1997. 

5. Dolan, M.E. Inhibition of DNA repair as a means of increasing the antitumor activity of DNA 

reactive agents. Advanced Drug Delivery Reviews, 26:105-118, 1997. 

6. Gamcsik, M.P., Dolan, M.E., Anderson, B.S., and Murray, D. Mechanisms of resistance to 

the toxicity of cyclophosphamide. Current Pharmaceutical Design, 5:587-605, 1999. 

7. Nagasubramanian, R. and Dolan, M.E. Temozolomide – Realizing the promise and potential. 

Current Opinion in Oncology, 15:412-418, 2003. 

8. Nagasubramanian, R. and Dolan, M.E. Pharmacogenomics – Racing toward personalized 

prescriptions. J Lab Med., 9:651-659, 2003. 

32

9. Shukla, S.J. and Dolan, M.E. Use of CEPH and nonCEPH cells in pharmacogenetic studies. 

Pharmacogenomics, 6:303-310, 2005. PMID16013961 

10. Rabik, C. A., Njoku, M.C., and Dolan, M.E. Inactivation of O 6 -alkylguanine DNA 

alkyltransferase as a means to enhance chemotherapy. Cancer Treatment Reviews, 32:261- 

276, 2006. PMID16698182 

11. Rabik, C.A. and Dolan, M.E. Molecular Mechanisms of Platinating Agents‘ Reistance Toxicity. 

Cancer Treatment Reviews, 33:9-23, 2007. PMID17084534 PMCID: PMC1855222 

12. Giacomini, K.M., Brett, C.M., Altman, R.B., Benowitz, N.L., Dolan, M.E., Flockhart, D.A., 

Johnson, J.A., Krauss, R.M., Kroetz, D.L., McLeod, H.L., Ratian, M.J., Relling, M.V., Roden, 

D.M., Schaefer, C.A., Shuldiner, A.R., Skaar, T., Tyndale, R.F., Weinshilboum, R.W., Weiss, 

S.T., Zineh, I. The pharmacogenetics research network: From SNP discovery to clinical drug 

response. Clin Pharm Ther., 81(3); 328-45, 2007. PMID17339863 

13. Hartford, C.M. and Dolan, M.E. Identifying Genetic Variants that Contribute to Chemotherapy- 

Induced Cytotoxicity. Pharmacogenetics, 8(9):1159-1168, 2007. PMID17924831 


14. Weiss ST, McLeod HL, Flockhart DA, Dolan ME, Benowitz NL, Johnson JA, Ratain MJ, 

Giacomini KM. Creating and evaluating genetic tests predictive of drug response. Nat Rev 

Drug Discov. 7:568-74, 2008. PMID18587383 PMCID: PMC2682785 

15. Zhang, W., Ratain, M.J., and Dolan, M.E. The HapMap Resource is Providing New Insights 

into Ourselves and its Application to Pharmacogenomics. Bioinformatics and Biology Insights, 

2:15-23, 2008. PMID18392109 PMCID: PMC2288550 

16. Zhang, W. and Dolan, M.E. On the Challenges of the HapMap Resource. 

Bioinformation, 2:238-239, 2008. PMID18317571 PMCID: PMC2258425 

17. Zhang, W., Duan, S., and Dolan, M.E. HapMap filter 1.0: A tool to preprocess the HapMap 

genotypic data for association studies, Bioinformation, 2:322-324, 2008. PMID18685717 


18. Zhang, W. and Dolan, M.E. Beyond the HapMap Genotypic Data: Prospects of Deep 

Resequencing Projects, Current Bioinformatics, 3:178-182, 2008. PMID: 20151045 PMCID: 

PMC2819736 

19. Zhang, W. and Dolan, M.E. Exploring the evolutionary history of the differentially expressed 

genes between human populations: action of recent positive selection, Evolutionary 

Bioinformatics Online, 4:171-179, 2008. PMID19030115 PMCID: PMC2585739 

20. Zhang, W., Huang, R.S., and Dolan, M.E. Integrating epigenomics into pharmacogenomic 

studies. Pharmacogenomics and Personalized Medicine, 1: 7–14, 2008. 

21. Yang, J., Bogni, A., Schuetz, E.G., Ratain, M., Dolan, M.E., McLeod, H., Gong, L., Thorn, C., 

Relling, M.V., Klein, T.E., Altman, R.B. Etoposide pathway, Pharmacogenet Genomics, 

19:552-3, 2009. 

33

22. Zhang, W., Huang, R.S., and Dolan, M.E. Cell-based models for discovery of 

pharmacogenomic markers of anticancer agent toxicity. Trends in Cancer Research, 2009 

23. O‘Donnell, P.H. and Dolan, M.E. Cancer Pharmacoethnicity: Ethnic Differences in 

Susceptibility to the Effects of Chemotherapy. Clin Cancer Res, 15:4806-14, 2009 PMID: 

19622575 PMCID: PMC2774468 

24. Zhang W., Huang S., Dolan M.E. Use of Cell Lines in the Investigation of Pharmacogenetic 

Loci. Current Pharmaceutical Design, 15:3782-95, 2009. PMID: 19925429 PMCID: 

PMC2782819 

25. Dolan M.E. Approaches to Identify Pharmacogenomic Markers. AACR Educational Book, 

2009. 

26. Welsh M., Mangravite L., Medina M., Tantisira K., Zhang, W., Huang R. S., McLeod H., Dolan 

M. E. Pharmacogenomic Discovery Using Cell-Based Models. Pharmacological Reviews. 

61:413-429, 2009. PMID: 20038569 PMCID: PMC2802425 

27. Pinto, N., Ludeman, S.M. Dolan, M. E. Pharmacogenetic Studies Related to 

Cyclophosphamide-based Therapy, Pharmacogenomics, 10(12): 1897-903, 2009. PMID: 

19958089 NIHMS: 171814 PMCID: PMC2820268 

28. Zhang W., Dolan, M.E. Emerging role of microRNAs in drug response. Current Opinion in 

Molecular Therapeutics, in Press, 2010 

Book Chapters 

1. Dolan, M.E., Morimoto, K., and Pegg, A.E. Specificity of alkyltransferases isolated from 

mammalian cells and E. coli. In: Repair of DNA Lesions Introduced by N-nitroso Compounds. 

Myrnes, B., Krokan, H. (eds.), Norwegian University Press, New York, pp. 101-111, 1986. 

2. Pegg, A.E., Scicchitano, D., Morimoto, K., and Dolan, M.E. Specificity of O 6 -alkylguanine- 

DNA-alkyltransferase. Proceedings IX International Symposium on N-nitroso-compounds, 

IARC, Lyon, 84:30-34, 1987. 

3. Pegg, A.E. and Dolan, M.E. Investigation of sequence specificity in DNA alkylation and repair 

using oligodeoxynucleotide substrates. In: DNA repair mechanisms and their biological 

implications in mammalian cells. Lambert, M.W., Laval, J. (eds.), Plenum Press, NY, pp. 45- 

49, 1989. 

4. Cockley, K.D., Dolan, M.E., Hendrickson, W., Kreider, J.W., and Howett, M.K. Analysis of 

human papillomavirus type 11 (HPV-11)-specific mRNA synthesis in HPV-infected human 

tissue in vivo. In: UCLA Symposium on Molecular and Cellular Biology New Series. Howley, 

P., Broker, T. (eds.), Alan R. Liss, Inc., N.Y., 24:393-403, 1990. 

5. Dolan, M.E. Importance of DNA repair in cancer chemotherapy. In: Principles of Cancer 

Drug Pharmacology. Schilsky R.L., Ratain, M., Milano G. (eds.), Marcel Dekker, Inc., New 

York, pp. 523-542, 1996. 

34

6. Dolan, M.E. Resistance to DNA-damaging agents. In: Encyclopedia of Cancer (Second 

Edition). Bertino, J.R. (ed). Academic Press, New York, 4:99-106, 2002. 

7. Dolan, M.E. and Pegg, A.E. Overcoming resistance to alkylating agents by inhibitors of O 6 - 

alkylguanine-DNA alkyltransferase, In: Cancer Drug Discovery and Development: DNA Repair 

in Cancer Therapy. Panasci L.C., Alaoui-Jamali M. (eds.), Humana Press, Totowa, N.J., 

2003. 

8. Dolan, M.E. and McLeod, H. Cell based models to identify genetic variants contributing to 

anticancer drug response. In: Pharmacogenomics, Anticancer Drug Discovery and Response. 

Innocenti, F. (ed.), Humana Press. 2008. 

9. Huang, R.S., Duan, S. and Dolan, M.E. Finding novel pharmacogenetic markers using cell 

lines: whole genome studies. In: Cancer Pharmacogenetics Advances in Experimental 

Medicine and Biology. Marsh, S. (ed.), Kluwer Academic/Plenum Publishers. Chapter 

submitted, 2007. 

10. Njiaju, U.O., and Dolan, M.E. Oncologic Drugs, under review, 2010. 

Lay Press 

1. The Press Association. Drug effects ‗vary in race groups‘. Mar 1, 2003 

2. Science Daily. Gene expression differences between Europeans and Africans affect, Feb 28, 

2008 

3. Reuters South Africa, South Africa. Trawl of two groups‘ genes shows differences. Feb 28, 

2008 

4. Washington Post, United States. Gene expression differences affect drug response. Feb 28, 

2008 

5. GenomeWeb News, NY. Gene expression study of African, European-Descended 

populations. Feb 28, 2008 

6. BBC News, UK. Race differences in immune genes. Feb 29, 2008 

7. Wall Street Journal, Tiny Gene Variations Can Even Alter Effect Of the Pills We Take, March 

21, 2008 

Abstract Book Cover Design 

1. Huang, R.S., Duan, S., Bleibel, W.K., Shukla, S.J., Clark, T.A., Blume, J.E., Dolan, M.E. 

CSHL Pharmacogenomics Meeting, 2006 

Abstracts (all abstracts listed represent presentations) 

1. Weinkam, R.J., Dolan, M.E. Quantitative dose-response relations for chloroethylnitrosoureas 

in cell culture: Effects of concentration, duration, temperature and structure on cytotoxicity. 

Proc. Am. Assoc. Cancer Res., 23:163, 1982. 

2. Weinkam, R.J., Dolan, M.E. Quantitative dose-response relations for cytotoxic alkylating 

agents in cell culture. International Cancer Congress, Seattle, USA, 1982. 

35

3. Dolan, M.E., Wiest, L., Scicchitano, D., Pegg, A.E. Rate of repair of O 6 -alkylguanine residues 

in DNA. Proc. Am. Assoc. Cancer Res., 25:430, 1984. 

4. Dolan, M.E., Morimoto, K., Pegg, A.E. Reduction of O 6 -alkylguanine-DNA alkyltransferase 

activity in HeLa cells exposed to O 6 -alkylguanines. Proc. Am. Assoc. Cancer Res., 26:99, 

1985. 

5. Dolan, M.E., Morimoto, K., Pegg, A.E. Specificity of alkyltransferases isolated from 

mammalian cells and E. coli. "Repair of DNA lesions introduced by N-nitrosocompounds." 

University of Tromso, Norway, June 30-July 2, 1985. 

6. Domoradzki, J., Maher, V.M., McCormick, J.J., Dolan, M.E., Pegg, A.E. Evidence that the 

potentially mutagenic lesions induced by MNNG in human cells are repaired by O 6 - 

methylguanine-DNA-methyltransferase (MT). Proc. Environ. Mutagen Soc, 27:394, 1986. 

7. Dolan, M.E., Young, G., Pegg, A.E. Pretreatment with O 6 -alkylguanine increases the 

sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents. Proc. 

Am. Assoc. Cancer Res., 27:100, 1986. 

8. Dolan, M.E., Scicchitano, D., Oplinger, M., Pegg, A.E. Repair of oligodeoxynucleotides 

containing O 6 -alkylguanine by O 6 -alkylguanine-DNA-alkyltransferase. Proc. Am. Assoc. 

Cancer Res., 28:117, 1987. 

9. Dolan, M.E., Larkin, G.L., English, H.F., Young, G., Pegg, A.E. Reduction of O 6 -alkylguanine- 

DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice 

by treatment with O 6 -methylguanine. Proc. Am. Assoc. Cancer Res., 28:260, 1987. 

10. Dolan, M.E., Oplinger, M., Young, G., Pegg, A.E. Sequence specificity of guanine 

methylation and repair. Proc. Am. Assoc. Cancer Res., 29:107, 1988. 

11. Pegg, A.E., Oplinger, M., Dolan, M.E. Investigation of sequence specificity in formation of 

O 6 methylguanine and its repair using oligodeoxynucleotide substrates. J. Cell Biochem., 

12A:274, 1988. 

12. Belinsky, S.A., Dolan, M.E., White, C.M., Pegg, A.E., Anderson, M.W. Cell specific 

differences in O 6 -methylguanine-DNA-alkyltransferase activity and removal of O 6 - 

methylguanine in rat pulmonary cells. J. Cell Biochem., 12A:257, 1988. 

13. Cockley, K.D., Dolan, M.E., Hendrickson, W., Kreider, J.W., Howett, M.K. Analysis of human 

papilloma virus type 11 (HPV-11)-specific mRNA synthesis in HPV-infected human tissue in 

vivo. J. Cell Biochem., 13C:204, 1989. 

14. Dolan, M.E., Norbeck, L., Clyde, C., Pegg, A.E. Expression of the mammalian 

alkyltransferase gene in chinese hamster ovary cells. Proc. Am. Assoc. Cancer Res., 30:147, 

1989. 

15. Dolan, M.E., Moschel, R.C., Pegg A.E. Depletion of O 6 -alkylguanine-DNA alkyltransferase by 

treatment with O 6 -benzylguanine. Proc. Am. Assoc. Cancer Res., 31:451, 1990. 

36

16. Dolan, M.E., Mitchell, R.B. Moschel, R.C., Pegg, A.E. Effect of O 6 -benzylguanine analogs on 

O 6 -alkylguanine-DNA alkyltransferase activity and on the sensitivity of cells to alkylating 

agents. Proc. Am. Assoc. Cancer Res., 32:375, 1991. 

17. Maher, V.M. Lukash, L., Boldt, J., Pegg, A.E., Dolan, M.E., McCormick, J.J. Effect of 

inhibition of repair of O 6 -methylguanine on mutations induced in diploid human cells by 

alkylating agents. Proc. Am. Assoc. Cancer Res., 32:112, 1991. 

18. Dolan, M.E., Mitchell, R.B., Moschel, R.C., Pegg, A.E. Effect of O 6 -benzylguanine on O 6 - 

alkylguanine-DNA alkyltransferase activity in vivo and on the sensitivity of human glioma 

xenografts to chloroethylnitrosoureas. Ninth International Conference on Brain Tumor 

Research and Therapy, 1991. 

19. Sarkar, A., Dolan, M.E., Pegg, A.E., Marton, L.J., Deen, D.F. Enhanced BCNU cytotoxicity 

under oxic and hypoxic conditions by pretreatment with O 6 -benzylguanine. Ninth International 

Conference on Brain Tumor Research and Therapy, 1991. 

20. Dolan, M.E., Moschel, R.C., Pegg, A.E., English, H.F. Effect of O 6 -benzylguanine on the 

sensitivity of a rat prostate tumor to the chemotherapeutic effects of BCNU. Proc. Am. Assoc. 

Cancer Res., 33:480, 1992. 

21. Mitchell, R.B., Chitre, A.A., Dolan, M.E. Effect of temozolomide or dacarbazine on the 

sensitivity of human tumor cells and xenografts to carmustine. Proc. Am. Assoc. Cancer Res., 

33:485, 1992. 

22. Dolan, M.E., Mitchell R.B., Pegg, A.E., Moschel, R.C., Grindey, G.B. Effect of O 6 - 

benzylguanine on the sensitivity of human tumor xenografts to BCNU. Proc. Am. Assoc. 

Cancer Res., 33:484, 1992. 

23. Mitchell, R.B., Dolan, M.E., Janisch, L., Ratain, M.J., Schilsky, R.L. A phase I study of a 

unique schedule of dacarbazine and carmustine. Proc. Am. Assoc. Cancer Res., 33:236, 

1992. 

24. Pegg, A.E., Byers, T.L., Dolan, M.E., McDougall, M.G., Moschel, R.C. Comparison of the 

effect of O-substituted purines and pyrimidines on mammalian and bacterial O 6 -alkylguanine- 

DNA alkyltransferase (AGT) activity. Proc. Am. Assoc. Cancer Res., 33:484, 1992. 

25. Bishop, R.E., Dunn, L.L., Dolan, M.E., Moschel, R.C. O 6 -Alkylguanine-DNA alkyltransferace 

(AGT) depletion in Rat4 cells affects transforming potencies of O 6 -alkylguanine residues 

incorporated into codon 12 of the H-ras gene. Proc. Am. Assoc. Cancer Res., 33:144, 1992. 

26. Vokes, E., Krishnasamy, S., Dolan, M.E., Ratain, M., Dohrmann, G., Hekmatpanah, J., 

Kolker, J., Weichselbaum, R., Schilsky, R., Berezin, F., Walter, P., Charette J. 5-Fluorouracil 

(5-FU), hydroxyurea (HU) with escalating doses of iododeoxyuridine (IUdR) and concomitant 

radiotherapy (XRT) for malignant gliomas (MGL): A clinical and pharmacologic analysis. 

Proc. Am. Assoc. Cancer Res., 33:212, 1992. 

27. Vokes, E.E., Dolan, M.E., Ratain, M.J., Ramirez, J., McEvilly, J.M., Luckett, P., Haraf, D.J., 

Weichselbaum, R.R., Kies, M., Kozloff, M. Cisplatin (CDDP), fluorouracil (5-FU), l-leucovorin 

(L-LV) and interferon alfa-2b (IFN) (PFL-IFN) for advanced head and neck cancer (HNC): A 

pharmacological analysis. Proc. Am. Assoc. Cancer Res., 34:205, 1993. 

37

28. Sarkar, A., Dolan, M.E., Marton, L.J., Pegg, A.E., Deen, D.F. Combined alphadifluoromethylornithine 

and O 6 -benzylguanine potentiate 1,3-bis(2-chloroethyl)-1-nitrosourea 

cytotoxicity in nitrosourea-resistant human brain tumor cells. Proc. Am. Assoc. Cancer Res., 

34:296, 1993. 

29. Marathi, U.K., Kroes, R.A., Dolan, M.E., Erickson, L.C. Prolonged depletion of O 6 - 

methylguanine DNA methyltransferase (MGMT) activity following exposure to O 6 - 

benzylguanine (BG) with or without streptozotocin (STZ) enhances 1,3 bis(2-chloroethyl) 1-1 

nitrosourea (BCNU) sensitivity in vitro. Proc. Am. Assoc. Cancer Res., 34:321, 1993. 

30. Pegg, A.E., Dolan, M.E., Friedman, H.S., Moschel, R.C. Inhibition of O 6 -alkylguanine-DNA 

alkyltransferase as a means to enhance the effectiveness of chemotherapeutic alkylating 

agents. Proc. Am. Assoc. Cancer Res., 34:565, 1993. 

31. Dolan, M.E., Pegg, A.E., Moschel, R.C., Vishnuvajjala, B.R., Flora, K.P., Grever, M.R., 

Friedman, H.S. Biodistribution and effectiveness of O 6 -benzylguanine administered in PEG 

400 or cremophor vehicles in human brain tumor xenografts. Proc. Am. Assoc. Cancer Res., 

35:319, 1994. 

32. Archer, G., Dolan, M.E., DeLeon, M., Pegg, A., Moschel, R., Bigner, D., Friedman, H. 

Biodistribution and metabolism of O 6 -benzylguanine after intrathecal administration in athymic 

rats. Proc. Am. Assoc. Cancer Res., 35:355, 1994. 

33. Marathi, U.K., Dolan, M.E., Erickson, L.C. Extended depletion of O 6 -methylguanine DNA 

methyltransferase (MGMT) activity following O 6 -benzyl 2'deoxyguanosine (dBG), or O 6 - 

benzylguanine (BG) combined with streptozotocin (STZ) treatment enhances 1,3 bis(2chloroethyl)-1-nitrosourea 

(BCNU) cytotoxicity. Proc. Am. Assoc. Cancer Res., 35:361, 1994. 

34. Marathi, U.K., Dolan, M.E., Erickson, L.C. Anti-neoplastic activity of sequenced 

administration of O 6 -benzylguanine (BG), streptozotocin (STZ), and 1,3 bis(2-chloroethyl)-1nitrosourea 

(BCNU), in vitro and in vivo. Proc. Am. Assoc. Cancer Res., 35:361, 1994. 

35. Friedman, H.S., Dolan, M.E., Kaufmann, S.H., Colvin, O.M., Griffith, O.W., Moschel, R.C., 

Schold, S.C., Bigner, D.D., Ali-Osman, F. Elevated DNA polymerase α, DNA polymerase β, 

and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is 

cross-resistant to nitrosoureas and topotecan. Proc. Am. Assoc. Cancer Res., 35:364, 1994. 

36. Chae, M-Y., Dolan, M.E., Swenn, K., Pegg, A.E., Moschel, R.C. Substituted O 6 - 

benzylguanine derivatives and their inactivation of human O 6 -alkylguanine-DNA 

alkyltransferase (AGT). Proc. Am. Assoc. Cancer Res., 35:394, 1994. 

37. Roy, S.K., Korzekwa, K.R., Gonzalez, F.J., Moschel, R.C., Dolan, M.E. Role of human liver 

microsomal and human cDNA-expressed cytochrome P450 in oxidative metabolism of O 6 - 

benzylguanine. Proc Am. Assoc Cancer Res., 36:142, 1995. 

38. Chae, M-Y., Swenn, K., Kanugula, S., Dolan, M.E., Pegg, A.E., Moschel, R.C. Improved 

inactivators of human O 6 -alkylguanine-DNA alkyltransferase. Proc Am. Assoc Cancer Res., 

36:369, 1995. 

38

39. Vokes, E.E., Mick, R., Kies, M., Malone, D., Dolan, M.E., Athanasiadis, I., Haraf, D.J., Mittal, 

B., Kozloff, M., Weichselbaum, R.R., Ratain, M.J. Fluorouracil pharmacodynamics of 

induction chemotherapy in advanced head and neck cancer. Proc. Am. Soc. Clin. Oncol., 

14:297, 1995. 

40. Benson, III, A.B., Olopade, O.I., Dolan, M.E., Moharhan, S., Ratain, M.J., Stucky-Marshall, L., 

Gupta, E., Harder, S., Rademaker, A. Phase I studies of single dose (normal volunteers) and 

daily low dose 4-methyl -5 (2-pyrazinyl)-1M 2-dithione -3-thiol (oltipraz; RP, 35972) in patients 

(pts) with resected colon polyps and first degree female relatives of breast cancer pts. Proc. 

Am. Soc. Clin. Oncol., 14:165, 1995. 

41. Gupta, E., Dolan, M.E., Mick, R., Wang, X., DeLeon, M., Baker, T., Benson, A.B., Ratain, 

M.J., Olopade, O.I. Phase I clinical evaluation of oltipraz (OLT) as a chemopreventive agent. 

Clin Pharmac. Ther., 57:176, 1995. 

42. Dolan, M.E., Ratain M.J., Roy, S., Gupta, E., Paras, P., Harder, S., Schilsky, R.L. 

Pharmacokinetics (PK) and pharmacodynamics (PD) of O 6 -benzylguanine (BG) in patients 

with advanced cancer. Proc. Am. Soc. Clin. Oncol., 15:176, 1996. 

43. Vokes, E., Johnston, P., Recant, W., Mick, R., Behan, K., Dolan, M.E., Ratain, M., Beckmann, 

E., Weichselbaum, R., Kozlof, M., Allegra, C. Thymidylate synthase (TS) expression in 

advanced head and neck cancer (HNC). Proc. Am. Soc. Clin. Oncol., 15:313, 1996. 

44. Yarosh, D., Dolan, M.E., Belanich, M., Kibitel, J., Garcia, Y., Kuzel, T., Pezen, D. Mycosis 

fungoides is deficient in the DNA repair enzyme O 6 -alkylguanine-DNA alkyltransferse: 

Implications for treatment with alkylating agents. Proc. Am. Assoc. Cancer Res., 38:390, 

1997. 

45. Friedman, H.S., Johnson, S., Dong, Q., Schold, S.C., Rasheed, A., Bigner, S., Ali-Osman, F., 

Dolan, M.E., Colvin, O.M., Houghton, P., Germaine, G., Drummond, J.T., Keir, S., Marcelli, S., 

Bigner, D.D., Modrich, P. Methylator resistance mediated by mismatch repair deficiency in a 

glioblastoma multiforme xenograft. Proc. Am. Assoc. Cancer Res., 38:522, 1997. 

46. Roy, S.K., Moschel, R.C., Dolan, M.E. Pharmacokinetics and metabolism of 8-substituted 

derivatives of O 6 -benzylguinine (BG). Proc. Am. Assoc. Cancer Res., 38:596, 1997. 

47. Dolan, M.E., Yarosh, D., McRae, B.L., Belanich, M., van Seventer, G., Kibitel, J., Garcia, Y., 

Pezen, D., Kuzel, T. T-cells in mycosis fungoides are deficient in O 6 -alkylguanine DNA 

alkyltransferase: Implications for treatment with alkylating agents. Proc. Am. Soc. Clin. 

Oncol., 1997. 

48. Sweeney, P.J., Mundt, A.J., Masters, G., Fasanmade, A., Dolan, M.E., Witt, M., Macdonald, 

R.L., Ratain, M., Vokes, E.E. Phase OI trial of iododeoxyuridine, 5-FU, hydroxyurea and 

concomitant RT for malignant gliomas: clinical and pharmacologic analysis. Proc Am. Soc. 

Clin. Oncol., 16:394a, 1997. 

49. Wali, R., Skarosi, S., Hart, J., Dolan, M.E., Paras, P., Lenchner, K., Khare, S., Bissonnette, 

M., Brasitus, T. Inhibition of O 6 -alkylguanine-DNA alkyltransferase augments tumor incidence 

in the azoxymethane model of rat colonic carcinogenesis. Gastroenterol., 112:A675, 1997. 

39

50. Schilsky, R.L., Dolan, M.E., Cooper, N., Roy, S., Vogelzang, N.J., Ratain, M.J. Phase I 

clinical trial of O 6 -benzylguanine plus carmustine in patients with advanced cancer. 7 th 

International Congress on Anti-Cancer Treatment, 1997. 

51. Long, L., Ratain, M.J., Schilsky, R.L., Fasanmade, A.A., and Dolan, M.E. Metabolism and 

pharmacokinetic modeling of O 6 -benzylguanine in humans. Proc. Am. Assoc. Cancer Res., 

39:324, 1998. 

52. Wu, M., Liebowitz, D.N., Mikolajczak, K.E., Lin, A.M., and Dolan, M.E. Sensitivity of mutant 

O 6 -alkylguanine-DNA alkyltransferases (AGT) to O 6 -benzylguanine (BG) and O 6 -benzyl-8oxoguanine 

(8-oxoBG). Proc Am. Assoc. Cancer Res., 39:517, 1998. 

53. Friedman, H., Pegg, A., Johnson, S., Loktinova, N., Dolan, M.E., Modrich, P., Struck, R., 

Brent, T., Ludeman, S., Bullock, N., Kilborn, C., Keir, S. Modulation of cyclophosphamide 

activity by O 6 -alkylguanine-DNA alkyltransferase. Proc. Am. Assoc. Cancer Res., 39:219, 

1998. 

54. Schilsky, R.L., Dolan, M.E., Bertucci, D., Cooper, N., Roy, S., Mani, S., Vogelzang, N.J., 

Ratain, M.J. Phase I clinical and pharmacologic study of O 6 -benzylguanine (BG) plus 

carmustine (BCNU) in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol., 17:198a, 

1998. 

55. Wu, M.H., Liebowitz, D.N., Mikolajczak, K.E., Lin, A.M., Smith, S., Williams, S.F., Dolan, M.E. 

Selective protection of bone marrow cells from alkylating agent toxicity. J. Hemato., 5:295, 

1998. 

56. Smith, S.L., Lin, A.M., Danet, G.H., Mikolajczak, K.E., Ng-Cashin, J., Wu, MH., Williams, S.F., 

Dolan, M.E., Liebowitz, D.N. Expansion of CD34 bright cells using FLT-3 ligand, stem cell 

factor, and thrombopoietin. J. Hemato., 5:287, 1998. 

57. Humerickhouse, R., Dolan, M.E., Brockstein, B., Haraf, D., Stenson, K., Kies, M., Sulzen, L., 

Wright, P., House, L., Ratain, M.J., and Vokes, E.E. Phase I study of a novel DPD inhibitor 

GW776C85 and oral 5-FU with RT in recurrent or advanced head and neck cancer. Proc. Am. 

Soc. Clin. Oncol., 17:394a, 1998. 

58. Wali, R., Skarosi, S., von Lintig, F., Hart, J., Boss, G., Dolan, M.E., Bissonenette, M., 

Brasitus, T. Inhibition of O 6 -alkylguanine-DNA alkyltranserase augments tumor incidence by 

K-ras-dependent and independent pathways. Gastroenterology 114, 1998. 

59. Rhines, L.D., Sampath, P., Tyler, B.M., Dolan, M.E., Weingart, J., Brem, H. O 6 - 

Benzylguanine potentiates the effects of locally delivered carmustine in an intracranial animal 

brain tumor model. Congress Neuro. Surg. Ann. Mtg., 1998. 

60. Long, L., Balis, F.M., McCully, C., Moschel, R.C., and Dolan, M.E. Plasma and CSF 

pharmacokinetics study of 8-substituted O 6 -benzylguanines in nonhumans primates. Proc Am 

Assoc Can Res, 40:288, 1999. 

61. Cai, Y., Wu, M.H., Ludeman, S.M., Friedman, H.S., and Dolan, M.E. Role of O 6 - 

Alkylguanine-DNA alkyltransferase (AGT) in protecting against cyclophosphamide-induced 

toxicity and mutagenicity. Proc Am Assoc Can Res, 40:153, 1999. 

40

62. Smith, S., Wu, M.H., Dolan, M.E., Danet, G., Lin, A.M., Williams, S.F., Liebowitz, D.L. Shortterm 

culture of CD34+ cells with Flt-3L, SCF, and TPO enhances EGFP reporter gene 

expression. ISEH, 26:64, 1999. 

63. Wu, M.H., Liebowitz, D.N., Smith, S.L., Lin, A.M., William, S.F., Dolan, M.E. Electroporation 

optimization for drug resistant gene introduction into human hematopoietic stem cells. Amer 

Soc Gene Ther, 2:732, 1999. 

64. Ewesuedo, R.B, Dolan, M.E. Bioavailability of oral O 6 -benzylguanine in rats. Ame Soc Clin 

Pharm Ther, 1999. 

65. Friedman, H.S., Pegg, A.E., Johnson, S.P., Dolan, M.E., Modrich, P.C., Struck, R., Keir, S., 

Bigner, D.D., Colvin, O.M. Enhancement of cyclophosphamide (CY) activity following O 6 - 

benzylguanine (O 6 -BG) mediated depletion of O 6 -alkylguanine-DNA alkyltransferase (AGT). 

Proc Am Assoc Cancer Res 40:296, 1999. 

66. Friedman, H.S., McLendon, R.E., Dolan, M.E., Pegg, A.E., Moschel, R.C., Colvin, O.M., 

Cokgor, Il, Friedman, A.H., Schold, S.C., Bigner, D.D., Modrich, P.L. The biology of sensitivity 

and resistance to the molecule (temozolomide). Proc Am Assoc Cancer Res 40:754, 1999. 

67. Smith, S.M., Cai, Y., Ludeman, S.M., Dolan, M.E., Effects of O 6 -benzylguanine (O 6 -BG) on 

ifosfamide-induced cytotoxicity in Chinese hamster ovary (CHO) cells. Proc Am Assoc 

Cancer Res, 41:98, 2000. 

68. Cai, Y., Wu, M.H., Dolan, M.E. Effects of O 6 -benzylguanine (BG) on alkylating agent-induced 

toxicity and mutagenicity in CHO cells expressing wild type and mutant O 6 -alkylguanine DNA 

alkyltransferases (AGT). Proc Am Assoc Cancer Res, 41:99, 2000. 

69. Balu, N., Colvin, O.M., Dolan, M.E., Gamcsik, M.P., Ludeman, S.M. O 6 -Alkylation of guanine 

by acrolein and chloroacetaldehyde: Synthesis and stability studies of authentic adducts. Proc 

Am Assoc Can Res, 41:95, 2000. 

70. Friedman, H.S., Pluda, J., Bigner, D.D., Pegg, A.E., Moschel, R.C., Cokgor, I., Rich, J., 

Friedman, A.H., Dolan, M.E. Phase I trial of O 6 -benzylguanine plus BCNU for patients with 

recurrent malignant glioma. Proc Am Assoc Can Res, 41:397, 2000. 

71. Humerickhouse, R.A., Lohrbach, K., Lin, L., Bosron, W.F., Dolan, M.E. Characterization of 

CPT-11 hydrolysis by human liver carboxylesterase isoforms HCE-1 and HCE-2. Proc Am 

Assoc Can Res, 41:701, 2000. 

72. Dolan, M.E., Posner, M.C., Radosta, J., Steinberg, G., Peabody, T., Bertucci, D., Vuyasin, L., 

Ratain, M.J. Determination of the optimal modulatory dose of O 6 -benzylguanine in patients 

with surgically resectable tumor. NCI-EORTC, 2000. 

73. Haroun, R. I., Li, K. W., Tyler, B. M., Radosta, J., Dolan, M. E., Weingart, J., Brem, H. 

Intracranial delivery of O 6 -benzylguanine (BG) reduces intracranial levels of O6-alkylguanine- 

DNA alkyltransferase. Congress of Neurological Surgeons, 2000. 

74. Dumas, M.C., Ryan, C.W., Dolan, M.E., Vogelzang, N.J., Stadler, W.M. A Phase II trial of 

oral temozolomide (TEM) with measurement of tumor O 6 -alkylguanine-DNA alkyltransferase 

41

(AGT) activity in patients (Pts) with metastatic renal cell ceancer (RCC). Proc Am Assoc 

Cancer Res, 19:1479, 2000. 

75. Ewesuedo, R.B., Dolan, M.E. O 6 -Alkylguanine-DNA alkyltransferases activity in pediatric 

solid tumors. Pediatric Academic Societies Meeting, 2001. 

76. Cai, Y., Ludeman, S.M., Chung, A.B., and Dolan, M.E. Effect of O 6 -benzylguanine on cell 

cycle, apoptosis and mutagenicity of nitrogen mustards. Proc Am Assoc Cancer Res, 42:200, 

2001. 

77. Elinoff, J., Delaney, S., Radosta, J., Moschel, R.C., Eisenbrand, G., and Dolan, M.E. Effect of 

AGT inactivation on cytotoxicity and antitumor activity of an androgen-linked nitrosourea. Proc 

Am Assoc Cancer Res, 42:204, 2001. 

78. Zöchbauer-Müller, S., Fong, K.M., Dolan, M.E., Virmani, A.K., Geradts, J., Vokes, E., Gazdar, 

A.F., and Minna, J.D. Frequent occurrence of 5‘CpG island methylation of the FHIT gene in 

lung, breast and oral cancer. Proc Am Assoc Cancer Res, 42:708, 2001. 

79. Cai, Y., and Dolan, M. E. Effect of O 6 -benzylguanine on cell cycle, apoptosis, and 

mutagenicity of cells treated with nitrogen mustards. 3 rd Annual Midwest DNA Repair 

Symposium, 2001. 

80. Quinn, J.A., Dolan, M.E., Pegg, A.E., Moschel, R.C., Pluda J., McLendon, R.E., Provenzale, 

J., Petros, W., Tourt-Uhlig, S., Rich, J.N., Gururangan, S., Affronti, L., Buchanan, W., Colvin, 

O., Stewart, E.S., Friedman, A.H., Bigner, D.D., and Friedman, H.S. Phase II trial of BCNU 

plus O 6 -benzylguanine for patients with recurrent or progressive malignant glioma. Proc Am 

Soc Clin Oncol, 20:251, 2001. 

81. Weingart J, Dolan ME, Rosenblum M, Tatter S, Judy K, Olson J, Bohan E, Fisher JD, for the 

NABTT CNS Consortium. Phase I study of Gliadel combined with a continuous intravenous 

infusion of O6-benzylguanine in patients with recurrent malignant glioma. SNO, 2001. 

82. Rosen, S., Guitart, J., Martone, B., Dolan, M.E, Pezen, D., Foss, F., McLendon, R., Friedman, 

H., Yarosh, D., and Kuzel, T. Phase II trial of temozolomide (TMZ) for treatment of mycosis 

fungoides/sezary syndrome (MF/SS). Proc Am Soc Clin Oncol, 21:140, 2002. 

83. Fishel, M.L., Connell, P., Siddiqui, N., Dolan, M.E. Effect of O 6 -benzylguanine on nitrogen 

mustard and cisplatin induced toxicity in head and neck cancer cells. Proc. Amer. Assoc. 

Can. Res., 43:784, 2002. 

84. Friedman, H.S., Keir, S.K., Pegg, A.E., Houghton, P.J., Colvin, M., Moschel, R.C. and Dolan, 

M.E. O 6 -Benzylguanine-mediated enhancement of CPT-11 plus temozolomide combination 

therapy. Proc. Amer. Assoc. Can. Res., 43:784, 2002. 

85. Rosenblum, M., Weingart, J., Dolan, M.E., Tatter, S., Judy, K., Olson, J., Bohan, E., and 

Fisher, J. Phase I study of Gliadel combined with a continuous intravenous infusion of O 6 - 

benzylguanine in patients with recurrent malignant glioma. Proc Am Soc Clin Oncol, 21:314, 

2002. 

86. Friedman, H.S., Pluda, J., Weingart, J., Brem, H., Evans, B., Petros, W., Rich, J., Tourt-Uhlig, 

S., Gururangan, S., Reardon, D., Sampson, J., Friedman, A., Provenzale, J., McLendon, R.E., 

42

Colvin, O.M., Bigner, D.D., Dolan, M.E., Pegg, A., Moschel, R., and Quinn, J.A. Phase I trail 

of temodar plus O 6 -benzylguanine in the treatment of patients with recurrent or progressive 

cerebral anaplastic gliomas. Proc Am Soc Clin Oncol, 21:311, 2002. 

87. Nagasubramanian, R., Ratain, M.J., Larson, R.A., and Dolan, M.E. Interindividual and 

interfamilial variability in susceptibility to camptothecin. Clin Pharm Ther, 71:136, 2002. 

88. Rosenblum, M., Weingart, J., Dolan, M.E., Tatter, S., Judy, K., Olson, J., Bohan, E., and 

Fisher, J for the NABTT CNS Consortium. Phase I Study of Gliadel Combined with a 

Continuous Intravenous Infusion of O 6 -Benzylguanine in Patients with Recurrent Malignant 

Glioma. Proc Am Soc Clin Oncol, 21:314, 2002. 

89. Fishel, M.L., Zuhowski, E.G., Durtan, L., Egorin, M., and Dolan, M.E. Enhancement of 

platinum-induced toxicity and DNA damage with O 6 -Benzylguanine (O 6 -BG). Proc Am Soc 

Can Res, 44:1088, 2003. 

90. Ludeman, S.M., Springer, J.B., Colvin, M.E., Chang, Y.H., Dolan, M.E., and Colvin, O.M. 1,3- 

Intramolecular alkylation reactions in isophosphoramide and phosphoramide mustards. Proc 

Amer Assoc Cancer Res, 44:695, 2003. 

91. Weingart, J., Dolan, M.E., Rosenblum, M., Tatter, S., Judy, K., Olson, J., Macenka, D., and 

Fisher, J., for the NABTT CNS Consortium. Phase I study of gliadel combined with a 

continuous intravenous infusion of O 6 -benzylguanine in patients with recurrent malignant 

glioma. SNO 2003. 

92. Fishel, M.L., Xinmin, L., Dolan, M.E. Genes important in modulation of cisplatin cytotoxicity. 

Proc Amer Assoc Cancer Res, 45:1151, 2004. 

93. Liu, W., Innocenti, F., Wu, M.H., Desai, A., Dolan, M.E., Cook, E.H., Ratain, M.J. Two SNPs 

in the epidermal growth factor receptor (EGFR) gene promoter are associated with gene 

expression in vitro. Proc Amer Assoc Cancer Res, 45:2101, 2004. 

94. Innocenti F., Undevia S.D., Chen P.X., Das, S. Ramirez, J., Dolan, M.E., Relling M.V., 

Kroetz, D.L., Ratain, M.J. Pharmacogenetic analysis of interindividual irinotecan 

pharmacokinetic variability: Evidence for a functional variant of ABCC2. Proc Am Soc Clin 

Oncol 23:129, 2004. 

95. Gajewski T.F., Sosman J., Peterson A.C., Gerson S., Dolan M.E., Vokes E. Phase II trial of 

O 6 -benzylguanin and BCNU in patients with advanced melanoma. Proc Am Soc Clin Oncol 

23:abstr 7524, 2004. 

96. Hansen R.J., Cherian M.M., Kogan S.C., Delaney S.M., Nagsubramanian R., Dolan M.E. 

Role of O 6 -alkylguanine-DNA alkyltransferase in protecting against long-term BCNU-induced 

toxicities in vivo Proc Amer Assoc Cancer Res, 2005. 

97. Shukla S., Badner J., Cheng, C., Bleibel W., Dolan M.E. Genome-wide approach to finding 

determinants of susceptibility to chemotherapeutic agents. ASCPT, 2005 

98. Rabik C.A., Fishel M.L., Dolan M.E. The role of the ER stress pathway in modulation of 

platinating agents. Proc Amer Assoc Cancer Res, 2005. 

43

99. Nanda, R, Dignam, J.J., Collins, C, Xu, J, Dolan, M.E., Olopade, O.I. BRCA1 promoter 

methylation confers sensitivity to cisplatin in vitro. San Antonio Breast Cancer Symposium, 

2005. 

100. Fishel, M.L., He, Y., Dolan, M.E., Kelley, M.R. Small molecule enhancement of cisplatin and 

temozolomide chemotherapeutic agents for the treatment of ovarian cancer. NCI- EORTC 

Annual Meeting, Philadelphia, PA, 2005. 

101. Bleibel, W., Duan, S., Zhang, W., Wu, X., Shukla, S., Badner, J., Dolan, M.E. Whole-genome 

approach to discovering determinants of susceptibility to anti-leukemic Agents. PGRN 

Meeting, St. Louis, MO, 2005 

102. Duan, S., Shukla, S.J., Badner, J.A., Wu, X. Bleibel, W.K. Dolan, M.E., Genome-wide 

discovery of loci influencing Cytotoxicity of Carboplatin and Cisplatin. PGRN Meeting, St. 

Louis, MO, 2005. 

103. Rabik, Cara A., Fishel, Lelissa L., Delaney, Shannon M., Tilby, Michael J., Dolan, M.E. O 6 - 

Benzylguanine Enhances DNA Damage Caused by Cisplatin in Head and Neck Cancer Cell 

Lines. Proc Amer Assoc Cancer Res, 2006. 

104. Shukla, S.J., Badner, J.A., Wu, X., Zhang, W., Bleibel, W.K., Duan, S., Dolan, M.E. A Novel 

Genome-wide pproach to finding determinants of chemotherapeutic susceptibility. Proc Amer 

Assoc Cancer Res, 2006. 

105. Hansen, R.J., Shannon, D., Nagasubramanian, R., Dolan, M.E. Role of AGT in protecting 

from chemotherapy-induced toxicity and mutations. Proc Amer Assoc Cancer Res, 2006. 

106. Zhang, W., Wu, X., Liu W., Dolan, M.E., Ratain, M.J. Genome-wide screen for DNA copy 

number changes correlated with cytotoxicity to EGFR-targeted agents. Proc Amer Asso. 

Cancer Res in Press, 2006. 

107. Hansen, R.J., Rabik, C.A., Delaney, S.M., Dolan, M.E.. Alkylguanine-DNA Alkyltransferase 

Inhibitors: Current Status. EORTC, 2006 

108. Dolan, M.E., Shukla, S.J., Duan, S., Bleibel, W.K., Huang, S.R., Badner, J.A., Clark, T., Chen, 

T.X., Schweitzer, A.C., Blume, J.E. A Novel Genome-wide Approach to Finding Determinants 

of Chemotherapeutic Susceptibility. EORTC, 2006 

109. Shukla, S. Duan, S. Badner, J. Clark, T. Chen, T. Schweitzer, A. Blume, J. Dolan, M.E. A 

Genome-wide Approach to Finding Determinants of Susceptibility to Chemotherapeutic 

Agents. CSHL Pharmacogenomics Meeting, November, 2006 

110. Duan, S. Bleibel, W., Huang, S.R. Zhang, W. Clark, T. Chen, T. Schweitzer, A. Blume, J. Cox, 

N. Dolan, M.E. Exon-level dissection of the cis-acting expression quantitative trait loci in 

human genome. CSHL Pharmacogenomics Meeting, November, 2006 

111. Huang, R.S. Duan, S. Zhang, W. Bleibel, W. Clark, T. Chen, T. Schweitzer, A. Blume, J. 

Dolan, M.E. Genes contributing to differences in daunorubicin-induced cytotoxicity in cell lines 

derived from Ceph and the yoruban populations. CSHL Pharmacogenomics Meeting, 

November, 2006 

44

112. Duan, S., Huang, R.S., Bleibel, W.K., Kistner, E.O., Clark, T.A., Chen, T.X., Schweitzer, A.C., 

Blume, J.E., Cox, H.J., Dolan, M.E. Expression quantitative trait loci that contribute to 

daunorubicin-induced cytotoxicity. PGRN Statistical Workshop, 2006 

113. Innocenti, F., Mirkov, S., Nagasubramanian, R., Ramirez, J., Liu, W., Hennessy, K., Das, S., 

Dolan, M.E., Cook, E., Ratain, M.J. Effect of the Werner‘s syndrome gene variant 4330>C on 

the cytotoxicity of camptotecin in lymphoblastoid cell lines. Proc Amer Assoc Cancer Res., in 

press, 2007 

114. Huang, R.S., Duan, S., Zhang, W., Bleibel, W.K., Clark, T.A., Chen, T.X., Schweitzer, A.C., 

Blume, J.E., Dolan, M.E. Genes Contributing to Differences in Daunorubicin-induced 

Cytotoxicity in Cell Lines Derived from CEPH and the Yoruban Populations. Proc. Amer. 

Assoc. Cancer Res., in press, 2007 

115. Yamini, B., Yu, X., Dolan, M.E., Wu, M.H., Weichselbaum, R.R. Inhibition of NF-κB activity by 

Temozolomide involves O 6 -methylguanine induced inhibition of p65 DNA-binding. Proc Amer 

Assoc Cancer Res., in press, 2007 

116. Hartford, C.M., Zhang, W., Kistner, E., Dolan, M.E. A Whole-genome approach to Identify 

Genetic Determinants of Cytarabine Cytotoxicity. ASPHO, in press, 2007 

117. Collins, C., Huo, D., Xu, J., Bleibel, W, Dolan, M.E., Olopade, O, Nanda, R. BRCA1 Promoter 

methylation using methylation specific PCR (MSP) does not correlate to response to 

chemotherapy in vitro. ASCO, under consideration, 2007 

118. Yin, B., Diers, M.D., Rathe, S.K., Delaney, S.M., Dolan, M.E., Lowe, S.W., Largaespada, D.A. 

Genetic dissection of chemoresistance mechanisms and development of reverse strategy in 

leukemia using cell culture and mouse transplantation models. AACR, 2007. 

119. Rabik, C.A., Delaney, S.M., Fishel, M.L., Dolan, M.E. Utilization of HPLC to determine a 

potential interaction between O 6 -benzylguanine and cisplatin. 233 rd ACS National Meeting, 

Chicago, IL. March, 2007. 

120. Huang, R.S., Duan S, Bleibel W.K., Kistner E.O., Clark T.A., Chen T.X., Schweitzer A.C., 

Blume J.E., Dolan M.E. A novel genome-wide appraoch to identify genetic variant that 

contribute to chemotherapy-induced cytotoxicity. Clinical pharmacology and Therapeutics, 

2007, Vol 81, Supplement1, S4-5 and S10 

121. Hartford C.M, Duan S, Shukla S.J., Dolan M.E. Determination of genetic factors important in 

susceptibility to cytarabine cytotoxicity. Clinical pharmacology and Therapeutics, 2007, Vol 81, 

Supplement1, S32. 

122. Huang, R.S., Duan, S., Bleibel, W.K., Kistner, E.O., Clark, T.A., Chen, T.X., Schweitzer, A.C., 

Blume, J.E., Dolan, M.E. A novel genome-wide approach to identify genetic variants that 

contribute to chemotherapy-induced cytotoxicity. 15 th . SPORE Investigators Workshop, 2007 

123. Rabik, C.A., Fishel, M.L., Holleran, J.L., Egorin, M.J., Dolan, M.E. Both DNA and the 

endoplasmic reticulum are cellular targets for enhancement of cisplatin cytotoxicity by O 6 - 

benzylguanine. AACR-EORTC-NCI Meeting, San Francisco, CA., 2007 

45

124. Huang, R.S., Zhang, W., Shukla, S.J., Duan, S., Bleibel, W.K., Hartford, C.M., Dolan, M.E. 

Unbiased cell-based models to identify genetic variants associated with chemotherapeutic 

induced toxicity. AACR Centennial Conference on Translational Cancer Medicine: 

Technologies to Treatment Conference, Singapore, Nov. 2007. 

125. Hartford, C.M., Duan, S., Kistner, E.O., Dolan, M.E. Genetic determinants of susceptibility to 

cytarabine arabinoside. ASCPT, 2007. 

126. Dolan, M.E., Duan, S., Bleibel, W., Huang, R.S., Zhang, W., Shukla, S., and Hartford, C. 

Unbiased cell-based models to identify genetic variants associated with chemotherapeutic– 

induced toxicity. Molecular Biosciences Retreat, Galena, IL 2007 

127. Innocenti, F., Kroetz, D.L., Schuetz, E., Dolan, M.E., Ramirez, J., Relling, M., Chen, P., Das, 

S., Rosner, G.L., Ratain, M.J. Comprehensive pharmacogenetics analysis of irinotecan 

neutropenia and pharmacokinetics. ASCPT, 2008. 

128. O‘Donnell, P.H., Zhang, W., Huang, S., Shukla, S.J., Dolan, M.E. Inter-ethnic differences as 

a means for identification of novel genetic polymorphisms governing cisplatin-induced toxicity. 

ASCPT, 2008. 

129. Paré, L., Evans, P., Duan, S., Zhang, W., Dolan, M.E., Innocenti, F. VEGF pathway genes: 

novel functional variations that are ethnic specific. AACR, under review, 2009. 

130. O‘Donnell, P.H., Zhang, W., Huang, R.S., Shukla, S.J., Gamazon, E., Stadler, W.M., Dolan, 

M.E. Inter-Ethnic Differences as a means for identification and validation of novel genetic 

polymorphisms governing CARBOplatin toxicity. AACR, under review, 2009. 

131. Duan, S., Dolan, E., Peter, M.E. Identification of microRNAs with similar biological functions. 

Submitted, Keystone Meeting, 2009. 

132. Cox, N.J., Gamazon, E., Zhang, W., Dolan, M.E., Konkashbaev, A., Nicolae, D.L. SNPs 

reproducibly associated with complex human traits are disproprortionately likely to predict 

gene transcript levels. Submitted, ASHG Meeting, 2009. 

133. Huang, R.S., Ziliak, D., Gamazon, E., Duan, S., Zhang, W., Kistner, E.O., Chen, P., Mi, S., 

Chenevix-Trench, G., Beesley, J., Johnatty, S., Chen, X., DeFazio, A., Das, S., Cox, N.J., 

Dolan, M.E. Discovery, replication and clinical validation of genetic variants associated with 

carboplatin-induced cytotoxicity in Caucasians. Submitted, ASHG Meeting, 2009. 

134. Gamazon, E., Duan, S., Konkashbaev, A., Zhang, W., Kistner, E., Nicolae, D., Dolan, M.E., 

Cox, N.J. SCAN: SNP and copy number annotation. Submitted, ASHG Meeting, 2009. 

135. Wheeler, H., Stark, A., Gamazon, E., Gorsic, L., Cox, N., Dolan, ME. Functional genomewide 

association studies of chemotherapeutic response in African populations. Submitted, 

CSHL Meeting, 2010. 

136. Wen, Y., Wheeler, H., Gorsic, L., Dolan, M.E. Heritability of Chemotherapeutic-induced 

Apoptosis. Submitted, CSHL Meeting, 2010. 

137. Njiaju, U., Wheeler, H., Dolan, M.E. Genome-wide Approach to Generate a Genetic 

Signature Predictive of Paclitaxel Response. Submitted, ASCPT Meeting, 2010. 

46

REVISED: 12/14/2010 11:28 AM 

47

Mary Eileen Dolan - Purdue University

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?